var title_f7_18_7456="Dental caries in SS";
var content_f7_18_7456=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F53927&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F53927&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cervical dental caries in Sj&ouml;gren's Syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The absence of a normal quantity of saliva in Sj&ouml;gren's Syndrome leads to a greatly increased incidence of dental caries. The cavities occur in particular in the apical area of the tooth, near the gum line.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Fox, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_18_7456=[""].join("\n");
var outline_f7_18_7456=null;
var title_f7_18_7457="Biliopancreatic diversion AGA";
var content_f7_18_7457=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Biliopancreatic diversion with duodenal switch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 443px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the American Gastroenterological Association. Klein S, Wadden T, Sugerman HJ. AGA technical review on obesity. Gastroenterology 2002; 123:882.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_18_7457=[""].join("\n");
var outline_f7_18_7457=null;
var title_f7_18_7458="Patient information: Hair loss in men and women (The Basics)";
var content_f7_18_7458=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15436\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/25/32149\">",
"         Hair loss in men and women",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/60/34760\">",
"          Alopecia areata",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/15/24817\">",
"         Patient information: Alopecia areata (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/56/17282\">",
"         Patient information: Hair loss in men and women (androgenetic alopecia) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hair loss in men and women (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hair-loss-in-men-and-women-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H470276293\">",
"      <span class=\"h1\">",
"       What causes hair loss?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common cause of hair loss is a condition called &ldquo;androgenetic alopecia.&rdquo; This condition is also known as &ldquo;male-pattern baldness.&rdquo; But that term is confusing, because the condition affects both men and women equally.",
"     </p>",
"     <p>",
"      Androgenetic alopecia can look different in men and women. Men often develop bald areas on the front and the top of the scalp. Women often have thinning hair on the top of the scalp, but usually do not lose all of the hair there (",
"      <a class=\"graphic graphic_figure graphicRef74652 \" href=\"UTD.htm?31/25/32149\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Another common cause of hair loss is called &ldquo;alopecia areata.&rdquo; This type of hair loss happens when the body&rsquo;s infection-fighting system gets confused and starts to attack the parts of the skin where hair grows. People with alopecia areata have big, usually round spots of hair missing (",
"      <a class=\"graphic graphic_picture graphicRef50613 \" href=\"UTD.htm?33/60/34760\">",
"       picture 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      There are many other reasons for hair loss. Some medical conditions and even some medicines can also cause hair loss.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H470276300\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse if you are very bothered by your hair loss, or if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You are not sure why you are losing your hair.",
"       </li>",
"       <li>",
"        Your hair loss occurs suddenly.",
"       </li>",
"       <li>",
"        You also have itching or pain on your scalp.",
"       </li>",
"       <li>",
"        You also don&rsquo;t feel well or feel very tired.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H470276307\">",
"      <span class=\"h1\">",
"       Are there tests I should have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with hair loss do not need tests. But your doctor or nurse might do tests to make sure your hair loss is not caused by a hormonal problem or another medical condition.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H470276314\">",
"      <span class=\"h1\">",
"       How is hair loss treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on what type of hair loss you have.",
"     </p>",
"     <p>",
"      If your hair loss is caused by a health problem, treating that problem can help. Other types of hair loss are treated with medicines that go on the scalp or that come in pills. Sometimes surgery is used to treat people with areas of hair that cannot grow back.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Androgenetic alopecia",
"        </strong>",
"        &ndash; These medicines can help hair regrow in people with androgenetic alopecia:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?37/20/38208?source=see_link\">",
"         Minoxidil",
"        </a>",
"        (sold as Rogaine&reg;) &ndash; This medicine is used in men and women. You can buy it without a prescription. It comes in a liquid or foam that you put on your head.",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?12/44/12996?source=see_link\">",
"         Finasteride",
"        </a>",
"        (sold as Propecia&reg;) &ndash; This medicine is meant for men. Doctors sometimes also give it to women who have been through menopause (meaning they have stopped having periods). It comes in a pill, and you need a prescription to buy it.",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/27/19893?source=see_link\">",
"         Spironolactone",
"        </a>",
"        (sold as Aldactone&reg;) &ndash; This medicine can help hair regrow in some women who do not have good results with",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?37/20/38208?source=see_link\">",
"         minoxidil",
"        </a>",
"        . It is not safe to use during pregnancy. Women who can get pregnant are often given birth control pills to prevent pregnancy while they are taking spironolactone. The medicine comes in a pill, and you need a prescription to buy it.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Alopecia areata",
"        </strong>",
"        &ndash; These are some examples of medicines that can help regrow hair in people with alopecia areata:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Medicines called steroids, which come in shots or creams and lotions. (These steroids are not the ones athletes take to build up muscle.) These steroids slow or stop the immune response that causes alopecia areata.",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?37/20/38208?source=see_link\">",
"         Minoxidil",
"        </a>",
"        (sold as Rogaine&reg;)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H470276321\">",
"      <span class=\"h1\">",
"       What if I am upset about my hair loss?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Losing your hair can be very tough. If you feel sad or anxious because of your hair loss, speak to your doctor or nurse. He or she can help you get the support you need.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H470276328\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/56/17282?source=see_link\">",
"       Patient information: Hair loss in men and women (androgenetic alopecia) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/15/24817?source=see_link\">",
"       Patient information: Alopecia areata (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?7/18/7458?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15436 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-D31E40A6FC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_18_7458=[""].join("\n");
var outline_f7_18_7458=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H470276293\">",
"      What causes hair loss?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H470276300\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H470276307\">",
"      Are there tests I should have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H470276314\">",
"      How is hair loss treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H470276321\">",
"      What if I am upset about my hair loss?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H470276328\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15436\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/25/32149\">",
"      Hair loss in men and women",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/60/34760\">",
"       Alopecia areata",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/15/24817?source=related_link\">",
"      Patient information: Alopecia areata (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/56/17282?source=related_link\">",
"      Patient information: Hair loss in men and women (androgenetic alopecia) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_18_7459="Vaginal cuff repair";
var content_f7_18_7459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Vaginal cuff repair during laparoscopic hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Lyons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_18_7459=[""].join("\n");
var outline_f7_18_7459=null;
var title_f7_18_7460="Anaplastic large cell lymphoma skin 2";
var content_f7_18_7460=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Primary cutaneous anaplastic large cell lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multicentric primary cutaneous anaplastic large cell lymphoma on the chest of a 36-year-old man.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Dermatology Online Atlas, www.dermis.net. Copyright &copy; 2012. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_18_7460=[""].join("\n");
var outline_f7_18_7460=null;
var title_f7_18_7461="Groin hernia anatomy";
var content_f7_18_7461=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Groin hernia anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 545px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Indirect inguinal hernias develop at the internal inguinal ring and are lateral to the inferior epigastric artery. Direct inguinal hernias occur through Hesselbach's triangle (outlined in blue) formed by the inguinal ligament inferiorly, the inferior epigastric vessels laterally, and the rectus muscle medially. Femoral hernias develop in the empty space at the medial aspect of the femoral canal, inferior to the inguinal ligament.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_18_7461=[""].join("\n");
var outline_f7_18_7461=null;
var title_f7_18_7462="Perampanel: Drug information";
var content_f7_18_7462=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Perampanel: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/4/20549?source=see_link\">",
"    see \"Perampanel: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F15405059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F15405061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      AMPA Glutamate Receptor Antagonist;",
"     </li>",
"     <li>",
"      Anticonvulsant, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F15657532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Partial seizures (adjunct):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patients",
"     <b>",
"      not",
"     </b>",
"     receiving enzyme-inducing AED regimens: Initial: 2 mg once daily at bedtime; may increase daily dose by 2 mg at weekly intervals based on response and tolerability. Recommended dose: 8-12 mg once daily at bedtime.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patients receiving enzyme-inducing AED regimens (eg, phenytoin, carbamazepine, oxcarbazepine): Initial: 4 mg once daily at bedtime; may increase daily dose by 2 mg at weekly intervals based on response and tolerability. Recommended dose: 8-12 mg once daily at bedtime.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F15657531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;12 years and Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F15657534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Increase dose no more frequently than every 2 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15657535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild impairment: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate impairment: No dosage adjustment necessary; monitor closely and consider slower titration based on response and tolerability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment: Use not recommended (has not been studied)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hemodialysis: Use not recommended (has not been studied)",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15657533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild impairment: Initial 2 mg once daily; may increase daily dose by 2 mg every 2 weeks based on response and tolerability. Maximum: 6 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate impairment: Initial 2 mg once daily; may increase daily dose by 2 mg every 2 weeks based on response and tolerability. Maximum: 4 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment: Use not recommended (has not been studied)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F15594338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F15405058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fycompa&trade;: FDA approved October 2012; anticipated availability currently unknown. Consult prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F15575719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM326088.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM326088.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15657538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer at bedtime. May be administered without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F15405063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive therapy in the treatment of partial-onset seizures (with or without generalized seizures)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F15607864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%: Central nervous system: Dizziness (16% to 43%), somnolence (9% to 18%), headache (13%), fatigue (8% to 12%), irritability (4% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Ataxia (1% to 8%), vertigo (3% to 5%), balance impaired (&le;5%), gait disturbance (4%), anxiety (2% to 4%), aggression (2% to 3%), hypersomnia (1% to 3%), anger (&le;3%), hypoesthesia (&le;3%), confusion (2%), coordination impaired (&le;2%), euphoria (&le;2%), memory impaired (&le;2%), mood changes (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Bruising (&le;2%), skin laceration (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyponatremia (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Weight gain (4% to 9%), nausea (6% to 8%), vomiting (4%), constipation (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Falling (5% to 10%), back pain (5%), dysarthria (1% to 4%), myalgia (3%), arthralgia (&le;3%), limb pain (&le;3%), limb injury (2%), musculoskeletal pain (2%), weakness (2%), paresthesia (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (3% to 4%), diplopia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (4%), upper respiratory tract infection (4%), oropharyngeal pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Head injury (3%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F15607842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15607843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Dizziness, fatigue (including lethargy and weakness), gait disturbances (including abnormal coordination, ataxia, and balance disorder), and somnolence may occur during therapy; patients should be cautioned about performing tasks which require alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuropsychiatric disorders:",
"     <b>",
"      [U.S. Boxed Warning]: Dose-related serious and/or life-threatening neuropsychiatric events (including aggression, anger, homicidal thoughts, hostility, and irritability) have been reported most often occurring in first 6 weeks of therapy in patients with or without pre-existing psychiatric disease; monitor patients closely especially during dosage adjustments and when receiving higher doses. Adjust dose or immediately discontinue use if severe or worsening symptoms occur. Inform patients and caregivers to contact their healthcare provider immediately if they experience any atypical behavioral and/or mood changes.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Not recommended for use in patients with severe impairment; dosage adjustment recommended for mild-to-moderate hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Not recommended for use in patients with severe impairment or on hemodialysis; use caution in patients with moderate impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants: Concomitant use with CNS depressant (including alcohol) may increase the risk of CNS depression. Use caution if a CNS depressant must be used concurrently with perampanel.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fall risk: Use with extreme caution in patients who are at risk of falls; use has been associated with falls and traumatic injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually (&ge;1 week) to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F15594443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F15594441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): Perampanel may enhance the CNS depressant effect of Alcohol (Ethyl). Alcohol may also worsen the negative behavioral and psychiatric effects of Perampanel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Perampanel. Management: Increase the perampanel starting dose to 4 mg/day when perampanel is used with carbamazepine.  Patients receiving this combination should be followed closely for response, especially with any changes to carbamazepine therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: Perampanel may enhance the CNS depressant effect of CNS Depressants.  Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Perampanel may decrease the serum concentration of Contraceptives (Progestins).  Management: Patients should use an alternative, non-hormonal based form of contraception for the duration of concurrent perampanel.  Both oral and non-oral progestin-based contraceptives are likely to be impacted by this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Perampanel. Management: Avoid use of perampanel with strong CYP3A inducers other than enzyme-inducing antiepileptic drugs (EIAEDs).  Increase perampanel starting dose to 4 mg/day when used with EIAEDs such as phenytoin, carbamazepine, or oxcarbazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin-Phenytoin: May decrease the serum concentration of Perampanel. Management: Increase the perampanel starting dose to 4 mg/day when perampanel is used with phenytoin/fosphenytoin.  Patients receiving this combination should be followed closely for response, especially with any changes to phenytoin/fosphenytoin therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Perampanel. Perampanel may increase the serum concentration of OXcarbazepine. Management: Increase the perampanel starting dose to 4 mg/day when perampanel is used with oxcarbazepine.  Patients receiving this combination should be followed closely for response, especially with any changes to oxcarbazepine therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Perampanel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F15607878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease perampanel levels. Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F15594322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F15607840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies at doses equivalent to the human dose (based on BSA). Contraceptives containing levonorgestrel may be less effective; additional nonhormonal forms of contraception are recommended during perampanel therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients exposed to perampanel during pregnancy are encouraged to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F15607841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F15657537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15657540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Seizure frequency/duration; suicidality (eg, suicidal thoughts, depression, behavioral changes); weight",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F15607880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The exact mechanism by which perampanel exerts antiseizure activity is not definitively known; it is a noncompetitive antagonist of the ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor on postsynaptic neurons. Glutamate is a primary excitatory neurotransmitter in the central nervous center causing many neurological disorders from neuronal over excitation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15607885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 95% to 96%; primarily albumin and alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive via primary oxidation mediated by CYP3A4 and/or CYP3A5 and sequential glucuronidation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 105 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 0.5-2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (48%); urine (22%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      French JA, Krauss GL, Biton V, et al, \"Adjunctive Perampanel for Refractory Partial-Onset Seizures: Randomized Phase III Study 304,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2012, 79(6):589-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/18/7462/abstract-text/22843280 /pubmed\" id=\"22843280 \" target=\"_blank\">",
"        22843280",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krauss GL, Bar M, Biton V, et al, \"Tolerability and Safety of Perampanel: Two Randomized Dose-Escalation Studies,\"",
"      <i>",
"       Acta Neurol Scand",
"      </i>",
"      , 2012, 125(1):8-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/18/7462/abstract-text/21883097 /pubmed\" id=\"21883097 \" target=\"_blank\">",
"        21883097",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krauss GL, Serratosa JM, Villanueva V, et al, \"Randomized Phase III Study 306: Adjunctive Perampanel for Refractory Partial-Onset Seizures,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2012, 78(18):1408-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/18/7462/abstract-text/22517103 /pubmed\" id=\"22517103 \" target=\"_blank\">",
"        22517103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87037 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-485ACEB782-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_18_7462=[""].join("\n");
var outline_f7_18_7462=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15405059\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15405061\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15657532\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15657531\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15657534\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15657535\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15657533\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15594338\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15405058\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15575719\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15657538\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15405063\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15607864\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15607842\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15607843\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15594443\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15594441\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15607878\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15594322\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15607840\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15607841\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15657537\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15657540\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15607880\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15607885\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87037\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87037|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/4/20549?source=related_link\">",
"      Perampanel: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_18_7463="Anorexia nervosa in adults: Pharmacotherapy";
var content_f7_18_7463=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anorexia nervosa in adults: Pharmacotherapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/18/7463/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/18/7463/contributors\">",
"     B. Timothy Walsh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/18/7463/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/18/7463/contributors\">",
"     Joel Yager, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/18/7463/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/18/7463/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/18/7463/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H5094772\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard treatment for anorexia nervosa consists of nutritional rehabilitation and psychotherapy, and is sometimes augmented with pharmacotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/1\">",
"     1",
"    </a>",
"    ]. However, there is little evidence supporting the use of medications [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. A few randomized trials suggest that adjunctive antipsychotics may possibly enhance weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/6\">",
"     6",
"    </a>",
"    ], but other psychotropic drugs have demonstrated little or no benefit in accelerating weight gain or relieving psychological symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/1,3-5\">",
"     1,3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Psychotropic pharmacotherapy for anorexia nervosa is reviewed here. The clinical manifestations, diagnosis, other treatments and outcome, and medical complications of anorexia nervosa and their management are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/7/3194?source=see_link\">",
"       \"Anorexia nervosa in adults: Diagnosis, associated clinical features, and assessment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=see_link\">",
"       \"Eating disorders: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=see_link\">",
"       \"Anorexia nervosa in adults and adolescents: Medical complications and their management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16550?source=see_link\">",
"       \"Anorexia nervosa in adults: Evaluation for medical complications and criteria for hospitalization to manage these complications\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5094779\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacotherapy is not an initial or primary treatment for anorexia nervosa [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. However, adjunctive pharmacotherapy is indicated for acutely ill patients who do not gain weight despite first line treatment with nutritional rehabilitation and psychotherapy, including patients with anticipatory anxiety when confronting a meal. In addition, adjunctive pharmacotherapy may possibly help reduce symptoms of depression and anxiety in patients who do not respond to first line treatment. Distorted thinking about body image and food usually does not respond to pharmacotherapy, nor do maintenance medications help delay or prevent subsequent episodes of anorexia nervosa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5094786\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with anorexia nervosa, standard treatment consists of nutritional rehabilitation and psychotherapy, which are supported by far more evidence than pharmacotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. Medications are used only for patients who do not respond to initial, standard treatment; if pharmacotherapy is added to the treatment regimen, the focus of treatment needs to remain upon nutritional rehabilitation and psychotherapy.",
"   </p>",
"   <p>",
"    Many patients with anorexia nervosa refuse pharmacotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/7\">",
"     7",
"    </a>",
"    ], particularly medications with side effects that include weight gain and the metabolic syndrome. This refusal stems from symptoms of anorexia nervosa that include lack of recognition of the seriousness of the disorder and ambivalence about weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/8\">",
"     8",
"    </a>",
"    ]. Negotiation and motivational interviewing (motivating the patient to gain weight by eliciting both the patient&rsquo;s reasons to do so and the patient&rsquo;s ambivalence about change) may help overcome this resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/9\">",
"     9",
"    </a>",
"    ]. Parents of adolescents may also refuse consent due to general concerns about drug safety, which may be allayed with education.",
"   </p>",
"   <p>",
"    For patients with anorexia nervosa who consent to medications, clinicians should initially prescribe a small dose because low weight patients are at increased risk for side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/1,5,9\">",
"     1,5,9",
"    </a>",
"    ]. In addition, depletion of body protein increases the percentage of unbound (free) drug in serum and depletion of body fat decreases the volume of distribution. Pharmacokinetic problems such as poor drug absorption or toxicity can occur because of starvation, vomiting, dehydration, or excess hydration [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/5\">",
"     5",
"    </a>",
"    ]. The antidepressant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    should not be used because it is associated with a higher incidence of seizures in patients with eating disorders, particularly patients who binge-eat and purge [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/1,10\">",
"     1,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians should consider the medical complications of anorexia nervosa when selecting a medication. As an example, starvation can cause bradycardia, hypotension, QT dispersion, diminished heart rate variability, and the long QT syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Thus, drugs that prolong cardiac conduction (",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"UTD.htm?2/48/2830\">",
"     table 1",
"    </a>",
"    ), such as antipsychotics and antidepressants, should be used cautiously in malnourished patients. Tricyclic antidepressants should not be used because of their cardiotoxicity. The medical complications of anorexia nervosa are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=see_link\">",
"     \"Anorexia nervosa in adults and adolescents: Medical complications and their management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3028991\">",
"    <span class=\"h1\">",
"     EVIDENCE OF EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials show that antipsychotics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ) may possibly be useful for restoring weight [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. However, many other psychotropic drugs have demonstrated little or no benefit for weight gain and other indications [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/1-5,16\">",
"     1-5,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several possible explanations for the general lack of demonstrated efficacy of pharmacotherapy in anorexia nervosa. One is that relatively few rigorous trials have been conducted [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/1,17\">",
"     1,17",
"    </a>",
"    ]. In addition, starvation and a lack of precursor molecules required for synthesis of neurotransmitters may prevent a medication response [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/18\">",
"     18",
"    </a>",
"    ]. Also, many patients refuse to participate in randomized pharmacotherapy trials or drop-out after enrollment; these problems make it difficult to interpret the results and to demonstrate a beneficial effect [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/7\">",
"     7",
"    </a>",
"    ]. As an example, a one-year randomized trial with 122 patients found that 55 percent dropped out, and much of the attrition occurred within the first five weeks.",
"   </p>",
"   <p>",
"    Most randomized trials of pharmacotherapy have been conducted within multimodal programs that specialize in eating disorders and are based at academically-affiliated hospitals [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/9\">",
"     9",
"    </a>",
"    ]. For anorexia nervosa patients who do not have access to specialized treatment, pharmacotherapy may conceivably provide greater benefits than those observed in the trials.",
"   </p>",
"   <p>",
"    Medication combinations have not been studied for any specific indication (eg, mood disorders) in patients with anorexia nervosa [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/4\">",
"     4",
"    </a>",
"    ], and should generally be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3028999\">",
"    <span class=\"h2\">",
"     Weight gain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goal of treatment in medically stable anorexic patients is weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3030016\">",
"    <span class=\"h3\">",
"     Antipsychotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjunctive treatment with antipsychotics has little to no benefit in restoring weight in patients with anorexia nervosa, based upon pooled results for different drugs that were evaluated in small randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of seven trials compared the effect of various antipsychotics with placebo upon body weight in 195 patients; the duration of treatment ranged from 7 to 12 weeks. Patients were assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      (N = 51),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      (N = 15),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      (N = 16), sulpiride (N = 9), placebo (N = 86), or treatment as usual in the one open label trial (N = 18) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/6\">",
"       6",
"      </a>",
"      ]. The analysis found a clinically modest benefit with a statistical trend favoring antipsychotics over",
"      <span class=\"nowrap\">",
"       placebo/usual",
"      </span>",
"      care; there was little to no heterogeneity across studies.",
"     </li>",
"     <li>",
"      A meta-analysis of six trials (166 patients) compared second generation antipsychotics (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      ) with placebo and found that the effects upon body mass index were comparable [",
"      <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/19\">",
"       19",
"      </a>",
"      ] &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Information about the pharmacology, administration, and side effects of antipsychotics is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1214159\">",
"    <span class=\"h4\">",
"     Olanzapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;For acutely ill patients not gaining weight with nutritional rehabilitation plus psychotherapy, we suggest adjunctive treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    2.5 mg to 10 mg per day. Olanzapine has been more widely studied for treatment of anorexia nervosa than any other antipsychotic [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/15,20,21\">",
"     15,20,21",
"    </a>",
"    ]. A meta-analysis of four homogeneous randomized trials compared olanzapine with placebo in 106 patients with anorexia nervosa, and found that weight gain was comparable [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/6\">",
"     6",
"    </a>",
"    ]. However, only one trial yielded a point estimate that favored placebo, and this trial had the fewest number of patients (N = 19) and thus the least precision in its estimate of treatment effects [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/22\">",
"     22",
"    </a>",
"    ]. Although the pooled trials showed no benefit to prescribing olanzapine, in our clinical experience it is reasonable to try the drug for patients who do not gain weight despite first line treatment with nutritional rehabilitation and psychotherapy.",
"   </p>",
"   <p>",
"    The primary adverse effect during short-term treatment of anorexia nervosa with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    is sedation. In a meta-analysis of three homogeneous randomized trials (68 patients with anorexia nervosa), drowsiness occurred in more patients who received olanzapine than placebo (89 versus 3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/6\">",
"     6",
"    </a>",
"    ]. This is consistent with a review of randomized trials and observational studies that found olanzapine (and other second-generation antipsychotics) often caused somnolence, but were otherwise safe and well tolerated in patients with anorexia nervosa [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/23\">",
"     23",
"    </a>",
"    ]. Nevertheless, the published experience is limited and there are concerns about metabolic complications and other problems that may arise with long-term treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1323286\">",
"    <span class=\"h4\">",
"     Other second-generation antipsychotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon individual studies, there is little or no evidence that other second-generation antipsychotics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    help restore weight in patients with anorexia nervosa. A randomized trial compared risperidone (mean dose 2.5 mg per day) with placebo in 40 adolescent and young adult females (mean age 16 years) with anorexia nervosa, and found no benefit with risperidone [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/24\">",
"     24",
"    </a>",
"    ]. In addition, open label studies have found that neither quetiapine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/25-27\">",
"     25-27",
"    </a>",
"    ] nor aripiprazole help restore weight [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/17\">",
"     17",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3030024\">",
"    <span class=\"h3\">",
"     Antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjunctive antidepressants do not help restore weight in patients with anorexia nervosa [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/3,16,17,28\">",
"     3,16,17,28",
"    </a>",
"    ]. A meta-analysis (four randomized trials, 146 patients) found that antidepressants were no more effective for weight gain than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/5\">",
"     5",
"    </a>",
"    ]. Three of the trials studied tricyclics, and the fourth studied the selective serotonin reuptake inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H240421\">",
"    <span class=\"h3\">",
"     Other pharmacologic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical experience and treatment guidelines suggest that an anxiolytic at a low dose (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    0.5 mg) may possibly reduce anticipatory anxiety when patients confront a meal [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. However, randomized trials indicate that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/25/19862?source=see_link\">",
"     cyproheptadine",
"    </a>",
"    , delta 9-tetrahydrocannabinol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , and zinc provide little or no benefit for weight gain compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/2,17,28\">",
"     2,17,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3029007\">",
"    <span class=\"h2\">",
"     Distorted thoughts about body image and food",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eating disorder psychopathology about body image and food generally does not respond to pharmacotherapy. A meta-analysis of five randomized trials compared the effect of antipsychotics with placebo in 114 patients with anorexia nervosa; patients were assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    (N = 30),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    (N = 15), sulpiride (N = 9), placebo (N = 42), or treatment as usual in the one open label trial (N = 18) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/6\">",
"     6",
"    </a>",
"    ]. The effects of antipsychotics and",
"    <span class=\"nowrap\">",
"     placebo/usual",
"    </span>",
"    care upon distorted thoughts about body image and food were comparable. In addition, randomized trials have found that antidepressants provide no benefit for treating eating disorder psychopathology [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/16,29\">",
"     16,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3029015\">",
"    <span class=\"h2\">",
"     Relapse prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;After restoration of body weight and normal eating behavior, relapse with substantial weight loss occurs frequently [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/30\">",
"     30",
"    </a>",
"    ]. Patients receiving standard treatment with maintenance psychotherapy do not benefit from adjunctive pharmacotherapy. A one-year randomized trial compared adjunctive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    (target dose 60 mg per day) and placebo in 93 adult patients who remitted from an episode of anorexia nervosa [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/29\">",
"     29",
"    </a>",
"    ]. All patients received weekly maintenance cognitive-behavioral therapy (CBT), and supplemental family therapy was also available. The proportion of patients who maintained a normal body mass index was similar for fluoxetine and placebo (27 versus 32 percent), and time to relapse was also similar for the two groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3029030\">",
"    <span class=\"h2\">",
"     Comorbid psychopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depressive disorders and anxiety disorders, including obsessive-compulsive disorder, are common in anorexia nervosa [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. Randomized trials show that adjunctive pharmacotherapy (eg, antidepressants), typically do not relieve these comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/16\">",
"     16",
"    </a>",
"    ]. Diagnosis of depressive disorders and anxiety disorders are discussed separately.",
"   </p>",
"   <p>",
"    Management of comorbid psychopathology depends upon its severity. Standard treatment of anorexia nervosa with nutritional rehabilitation plus psychotherapy often resolves mild to moderate comorbid depressive or anxiety disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. Although randomized trials have found no benefit in prescribing antidepressants for comorbid depression and anxiety, in our clinical experience it is reasonable to try an antidepressant (eg, a selective serotonin reuptake inhibitor) for patients with severe comorbid depression or anxiety that persists despite weight restoration. Tricyclic antidepressants are avoided because of concerns about cardiotoxicity in malnourished patients, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    is contraindicated in patients with eating disorders because it is associated with a higher incidence of seizures in patients with eating disorders. (See",
"    <a class=\"local\" href=\"#H5094786\">",
"     'General principles'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition, adjunctive treatment with second-generation antipsychotics may possibly ameliorate depressive symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/23\">",
"     23",
"    </a>",
"    ]. A meta-analysis of four randomized trials compared antipsychotics with placebo in 103 patients with anorexia nervosa; patients were assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    (N = 36),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    (N = 15), placebo (N = 40), or treatment as usual in the one open label trial (N = 18) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/6\">",
"     6",
"    </a>",
"    ]. The analysis found a clinically small to moderate benefit with a statistical trend favoring antipsychotics over",
"    <span class=\"nowrap\">",
"     placebo/usual",
"    </span>",
"    care; the heterogeneity across studies was small to moderate. However, the published experience is limited and there are concerns about metabolic complications that may arise with long-term treatment.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     Quetiapine",
"    </a>",
"    may possibly reduce symptoms of anxiety. An open label randomized trial compared quetiapine with treatment as usual in 33 patients with anorexia nervosa, and found less anxiety in patients who received quetiapine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7463/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/16/25858?source=see_link\">",
"       \"Patient information: Anorexia nervosa (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5094835\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The standard treatment for patients acutely ill with anorexia nervosa is nutritional rehabilitation plus psychotherapy. However, patients not gaining weight despite standard treatment are candidates for adjunctive pharmacotherapy, including patients with anticipatory anxiety when confronting a meal. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=see_link&amp;anchor=H251810#H251810\">",
"       \"Eating disorders: Treatment\", section on 'Anorexia nervosa'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H5094779\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Low weight patients treated with pharmacotherapy are at increased risk for side effects and should initially receive a small dose.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       Bupropion",
"      </a>",
"      should not be used because it is associated with a higher incidence of seizures in patients with eating disorders. Medical complications of anorexia nervosa should also be considered. As an example, drugs (",
"      <a class=\"graphic graphic_table graphicRef57431 \" href=\"UTD.htm?2/48/2830\">",
"       table 1",
"      </a>",
"      ) that impact cardiac function, such as antipsychotics and antidepressants (especially tricyclic agents), should be used cautiously in malnourished patients. (See",
"      <a class=\"local\" href=\"#H5094786\">",
"       'General principles'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=see_link\">",
"       \"Anorexia nervosa in adults and adolescents: Medical complications and their management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For acutely ill patients not gaining weight with nutritional rehabilitation plus psychotherapy, we suggest adjunctive treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      2.5 mg to 10 mg per day, rather than other medications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In addition, a low dose of an anxiolytic, eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      0.5 mg, may reduce anticipatory anxiety when patients confront a meal. (See",
"      <a class=\"local\" href=\"#H1214159\">",
"       'Olanzapine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H240421\">",
"       'Other pharmacologic agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Psychopathology about body image and food generally does not respond to pharmacotherapy. (See",
"      <a class=\"local\" href=\"#H3029007\">",
"       'Distorted thoughts about body image and food'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of choice for patients who have recovered from an episode of anorexia nervosa is maintenance psychotherapy; adjunctive pharmacotherapy is not beneficial. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=see_link&amp;anchor=H251954#H251954\">",
"       \"Eating disorders: Treatment\", section on 'Psychotherapy'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H3029015\">",
"       'Relapse prevention'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Mild to moderate comorbid depressive or anxiety disorders often resolve with standard treatment consisting of nutritional rehabilitation plus psychotherapy. For severe comorbid disorders that do not respond to standard treatment, it is reasonable to initially try a selective serotonin reuptake inhibitor (SSRI). Severe depression that is unresponsive to an SSRI may perhaps respond to a second-generation antipsychotic. (See",
"      <a class=\"local\" href=\"#H3029030\">",
"       'Comorbid psychopathology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7463/abstract/1\">",
"      American Psychiatric Association. Treatment of patients with eating disorders,third edition. American Psychiatric Association. Am J Psychiatry 2006; 163:4.",
"     </a>",
"    </li>",
"    <li>",
"     Kaye, WH, Walsh, BT. Psychopharmacology of eating disorders. In: Neuropsychopharmacology: The Fifth Generation of Progress, Davis KL, Charney D, Coyle JT, Nemeroff C (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2002. p.1675.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7463/abstract/3\">",
"      Bulik CM, Berkman ND, Brownley KA, et al. Anorexia nervosa treatment: a systematic review of randomized controlled trials. Int J Eat Disord 2007; 40:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7463/abstract/4\">",
"      Crow SJ, Mitchell JE, Roerig JD, Steffen K. What potential role is there for medication treatment in anorexia nervosa? Int J Eat Disord 2009; 42:1.",
"     </a>",
"    </li>",
"    <li>",
"     Eating Disorders: Core Interventions in the Treatment of and Management of Anorexia Nervosa, Bulimia Nervosa and Related Eating Disorders. National Institute for Clinical Excellence, Clinical Guideline 9. file://guidance.nice.org.uk (Accessed on December 22, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7463/abstract/6\">",
"      Kishi T, Kafantaris V, Sunday S, et al. Are antipsychotics effective for the treatment of anorexia nervosa? Results from a systematic review and meta-analysis. J Clin Psychiatry 2012; 73:e757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7463/abstract/7\">",
"      Halmi KA, Agras WS, Crow S, et al. Predictors of treatment acceptance and completion in anorexia nervosa: implications for future study designs. Arch Gen Psychiatry 2005; 62:776.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     Andersen, AE, Yager, J. Eating disorders. In: Kaplan &amp; Sadock's Comprehensive Textbook of Psychiatry, volume I, ninth edition, Sadock BJ, Sadock VA, Ruiz P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2009. p.2128.",
"    </li>",
"    <li>",
"     Wellbutrin (bupropion hydrochloride) Prescribing Information July 2009 file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103318.htm (Accessed on January 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7463/abstract/11\">",
"      Cooke RA, Chambers JB, Singh R, et al. QT interval in anorexia nervosa. Br Heart J 1994; 72:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7463/abstract/12\">",
"      Goldberg SJ, Comerci GD, Feldman L. Cardiac output and regional myocardial contraction in anorexia nervosa. J Adolesc Health Care 1988; 9:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7463/abstract/13\">",
"      Melanson EL, Donahoo WT, Krantz MJ, et al. Resting and ambulatory heart rate variability in chronic anorexia nervosa. Am J Cardiol 2004; 94:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7463/abstract/14\">",
"      Bissada H, Tasca GA, Barber AM, Bradwejn J. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2008; 165:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7463/abstract/15\">",
"      Dunican KC, DelDotto D. The role of olanzapine in the treatment of anorexia nervosa. Ann Pharmacother 2007; 41:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7463/abstract/16\">",
"      Claudino AM, Hay P, Lima MS, et al. Antidepressants for anorexia nervosa. Cochrane Database Syst Rev 2006; :CD004365.",
"     </a>",
"    </li>",
"    <li>",
"     Kaplan, AS, Howlett, A. Pharmacotherapy for anorexia nervosa. In: The Treatment of Eating Disorders: A Clinical Handbook, Grilo CM, Mitchell JE (Eds), The Guilford Press, New York 2010. p.175.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7463/abstract/18\">",
"      Bosanac P, Norman T, Burrows G, Beumont P. Serotonergic and dopaminergic systems in anorexia nervosa: a role for atypical antipsychotics? Aust N Z J Psychiatry 2005; 39:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7463/abstract/19\">",
"      Lebow J, Sim LA, Erwin PJ, Murad MH. The effect of atypical antipsychotic medications in individuals with anorexia nervosa: A systematic review and meta-analysis. Int J Eat Disord 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7463/abstract/20\">",
"      Leggero C, Masi G, Brunori E, et al. Low-dose olanzapine monotherapy in girls with anorexia nervosa, restricting subtype: focus on hyperactivity. J Child Adolesc Psychopharmacol 2010; 20:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7463/abstract/21\">",
"      Attia E, Kaplan AS, Walsh BT, et al. Olanzapine versus placebo for out-patients with anorexia nervosa. Psychol Med 2011; 41:2177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7463/abstract/22\">",
"      Kafantaris V, Leigh E, Hertz S, et al. A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol 2011; 21:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7463/abstract/23\">",
"      McKnight RF, Park RJ. Atypical antipsychotics and anorexia nervosa: a review. Eur Eat Disord Rev 2010; 18:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7463/abstract/24\">",
"      Hagman J, Gralla J, Sigel E, et al. A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study. J Am Acad Child Adolesc Psychiatry 2011; 50:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7463/abstract/25\">",
"      Powers PS, Bannon Y, Eubanks R, McCormick T. Quetiapine in anorexia nervosa patients: an open label outpatient pilot study. Int J Eat Disord 2007; 40:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7463/abstract/26\">",
"      Bosanac P, Kurlender S, Norman T, et al. An open-label study of quetiapine in anorexia nervosa. Hum Psychopharmacol 2007; 22:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7463/abstract/27\">",
"      Court A, Mulder C, Kerr M, et al. Investigating the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people: a pilot study. J Psychiatr Res 2010; 44:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7463/abstract/28\">",
"      Zhu AJ, Walsh BT. Pharmacologic treatment of eating disorders. Can J Psychiatry 2002; 47:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7463/abstract/29\">",
"      Walsh BT, Kaplan AS, Attia E, et al. Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. JAMA 2006; 295:2605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7463/abstract/30\">",
"      Kaplan AS, Walsh BT, Olmsted M, et al. The slippery slope: prediction of successful weight maintenance in anorexia nervosa. Psychol Med 2009; 39:1037.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14743 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-4F5D24ED7D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_18_7463=[""].join("\n");
var outline_f7_18_7463=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5094835\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5094772\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5094779\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5094786\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3028991\">",
"      EVIDENCE OF EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3028999\">",
"      Weight gain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3030016\">",
"      - Antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1214159\">",
"      Olanzapine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1323286\">",
"      Other second-generation antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3030024\">",
"      - Antidepressants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H240421\">",
"      - Other pharmacologic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3029007\">",
"      Distorted thoughts about body image and food",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3029015\">",
"      Relapse prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3029030\">",
"      Comorbid psychopathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5094835\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14743\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14743|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/48/2830\" title=\"table 1\">",
"      Causes of long QT syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=related_link\">",
"      Anorexia nervosa in adults and adolescents: Medical complications and their management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/7/3194?source=related_link\">",
"      Anorexia nervosa in adults: Diagnosis, associated clinical features, and assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16550?source=related_link\">",
"      Anorexia nervosa in adults: Evaluation for medical complications and criteria for hospitalization to manage these complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=related_link\">",
"      Eating disorders: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=related_link\">",
"      First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/16/25858?source=related_link\">",
"      Patient information: Anorexia nervosa (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_18_7464="Blepharitis eye";
var content_f7_18_7464=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F85896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F85896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Blepharitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Blepharitis is associated with crusting of the eyelashes, thickening of the eyelids, telangiectatic vessels along the lid margins, and plugging of the meibomian glands.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2nd ed, Tasman W, Jaeger E (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_18_7464=[""].join("\n");
var outline_f7_18_7464=null;
var title_f7_18_7465="Sertraline: Pediatric drug information";
var content_f7_18_7465=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sertraline: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"    see \"Sertraline: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/43/23222?source=see_link\">",
"    see \"Sertraline: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zoloft&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F220685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Sertraline&reg;;",
"     </li>",
"     <li>",
"      CO Sertraline;",
"     </li>",
"     <li>",
"      Dom-Sertraline;",
"     </li>",
"     <li>",
"      GD-Sertraline;",
"     </li>",
"     <li>",
"      Mylan-Sertraline;",
"     </li>",
"     <li>",
"      Nu-Sertraline;",
"     </li>",
"     <li>",
"      PHL-Sertraline;",
"     </li>",
"     <li>",
"      PMS-Sertraline;",
"     </li>",
"     <li>",
"      ratio-Sertraline;",
"     </li>",
"     <li>",
"      Riva-Sertraline;",
"     </li>",
"     <li>",
"      Sandoz-Sertraline;",
"     </li>",
"     <li>",
"      Teva-Sertraline;",
"     </li>",
"     <li>",
"      Zoloft&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1055426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidepressant, Selective Serotonin Reuptake Inhibitor (SSRI)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1055418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"      see \"Sertraline: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-12 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depression:",
"     <b>",
"      Note:",
"     </b>",
"     Not FDA approved: Initial: 12.5-25 mg once daily; titrate dose upwards if clinically needed; may increase by 25-50 mg/day increments at intervals of at least 1 week; mean final dose in 21 children (8-18 years of age) was 100 &plusmn; 53 mg or 1.6 mg/kg/day (n=11); range: 25-200 mg/day; maximum dose: 200 mg/day (Dopheide, 2006; Tierney, 1995); avoid excessive dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Obsessive-compulsive disorder: Initial: 25 mg once daily; titrate dose upwards if clinically needed; increase by 25-50 mg/day increments at intervals of at least 1 week; range: 25-200 mg/day; maximum dose: 200 mg/day; avoid excessive dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents 13-17 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depression: Initial 25-50 mg once daily; titrate dose upwards if clinically needed; may increase by 50 mg/day increments at intervals of at least 1 week; mean final dose in 13 adolescents was 110 &plusmn; 50 mg or about 2 mg/kg/day (McConville, 1996); in another study using a slower titration, the mean dose at week 6 was 93 mg (n=41) and at week 10 was 127 mg (n=34) (Ambrosini, 1999); range: 25-200 mg/day; maximum dose: 200 mg/day (Dopheide, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Obsessive-compulsive disorder: Initial: 50 mg once daily; titrate dose upwards if clinically needed; increase by 50 mg/day increments at intervals of at least 1 week; range: 25-200 mg/day; maximum dose: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depression and obsessive-compulsive disorder: Initial: 50 mg once daily; titrate dose upwards if clinically needed; increase by 50 mg/day increments at intervals of at least 1 week; range: 50-200 mg/day; maximum dose: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Panic disorder, post-traumatic stress disorder, and social anxiety disorder: Initial: 25 mg once daily; increase dose after 1 week to 50 mg once daily; titrate dose further if clinically needed; increase by 50 mg/day increments at intervals of at least 1 week; range: 50-200 mg/day; maximum dose: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Premenstrual dysphoric disorder: Initial: 50 mg/day given daily throughout the menstrual cycle",
"     <b>",
"      or",
"     </b>",
"     only during the luteal phase of the menstrual cycle (depending on assessment of physician); may increase if needed by 50 mg increments per menstrual cycle; maximum dose when using daily dosing throughout the menstrual cycle: 150 mg/day; maximum dose when dosing only during the luteal phase of the menstrual cycle: 100 mg/day.",
"     <b>",
"      Note:",
"     </b>",
"     If using a 100 mg/day dose with luteal phase dosing, use a 50 mg/day titration step for 3 days at the beginning of each luteal phase dosing period.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     None needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Use with caution and in reduced doses",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F220658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [concentrate]: 20 mg/mL (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zoloft&reg;: 20 mg/mL (60 mL) [contains ethanol 12%, menthol, natural rubber/natural latex in packaging]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg, 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zoloft&reg;: 25 mg, 50 mg, 100 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F220642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089832.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089832.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1055430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be administered without regard to food; avoid administration with grapefruit juice; administer once daily dosage in morning or evening. Must dilute oral concentrate before use; measure dose with dropper provided and mix with 4 ounces of water, orange juice, lemonade, ginger ale, or lemon/lime soda; do not mix with other liquids; take dose immediately after mixing, do not mix ahead of time; sometimes a slight haze may be seen after mixing (this is normal)",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1055421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1055429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of  obsessive-compulsive disorder (FDA approved in ages &ge;6 years and adults); treatment of major depressive disorder, panic disorder (with or without agoraphobia), post-traumatic stress disorder, premenstrual dysphoric disorder, and social anxiety disorder (social phobia) (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F220738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Sertraline may be confused with selegiline, Serevent&reg;, Soriatane&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zoloft&reg; may be confused with Zocor&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F220735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, dizziness, fatigue, headache, hypoesthesia, insomnia, malaise, nervousness, pain, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Decreased libido, impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, appetite increased, constipation, diarrhea, dyspepsia, flatulence, nausea, vomiting, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Ejaculatory disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, hypertonia, myalgia, paresthesia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Abnormal vision, visual difficulty",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, yawning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal pain, acute renal failure, agranulocytosis, allergic reaction, anaphylactoid reaction, angioedema, aplastic anemia, atrial arrhythmia, AV block, bilirubin increased, blindness, bradycardia, cataract, dystonia, extrapyramidal symptoms, galactorrhea, gum hyperplasia, gynecomastia, hallucinations, hepatic failure, hepatitis, hepatomegaly, hyperglycemia, hyperprolactinemia, hypothyroidism, jaundice, leukopenia, lupus-like syndrome, micturition disorders, neuroleptic malignant syndrome, oculogyric crisis, serotonin syndrome, SIADH, Stevens-Johnson syndrome (and other severe dermatologic reactions), optic neuritis, pancreatitis (rare), photosensitivity, priapism, psychosis, PT/INR increased, pulmonary hypertension, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, serum sickness, thrombocytopenia, torsade de pointes, transaminases increased, vasculitis, ventricular tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Pediatric patients: Additional adverse reactions reported: Aggressiveness, epistaxis, hyperkinesia, purpura, sinusitis, urinary incontinence",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1055434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sertraline or any component; use of MAO inhibitors within 14 days (potentially fatal reactions may occur); concurrent use of pimozide; oral concentrate is contraindicated in patients receiving disulfiram (contains 12% alcohol)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1055417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with seizure disorders, concomitant illnesses that may effect hepatic metabolism or hemodynamic responses (eg, unstable cardiac disease, recent MI), and in suicidal patients; use with caution and decrease dose in patients with hepatic dysfunction; may result in hyponatremia, SIADH, significant weight loss (monitor weight and growth in pediatric patients), decrease in serum uric acid (mild uricosuric effect, use with caution in patient at risk of uric acid nephropathy), activation of mania/hypomania, or abnormal bleeding; SSRIs may increase risk of bleeding (eg, upper GI bleeding) especially in patients receiving nonselective NSAIDs, aspirin, or other drugs that affect coagulation. Use with caution during late third trimester of pregnancy [newborns may experience adverse effects or withdrawal symptoms (consider risk and benefits); exposure to SSRIs late in pregnancy may also be associated with an increased risk for persistent pulmonary hypertension of the newborn (Chambers, 2006)]. SSRI-associated vomiting is two- to threefold more prevalent in children compared to adolescents; it is more prevalent in adolescents compared to adults (Safer, 2006). Children may experience some adverse effects not reported in adults, including aggressive reaction, epistaxis, hyperkinesia, purpura, sinusitis, urinary incontinence.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1055416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clinical worsening of depression or suicidal ideation and behavior may occur in children and adults with major depressive disorder",
"     <b>",
"      [U.S. Boxed Warnings]",
"     </b>",
"     . In clinical trials, antidepressants increased the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (18-24 years of age) with major depressive disorder and other psychiatric disorders. This risk must be considered before prescribing antidepressants for any clinical use. Short-term studies did",
"     <b>",
"      not",
"     </b>",
"     show an increased risk of suicidality with antidepressant use in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients of all ages who are treated with antidepressants for any indication require appropriate monitoring and close observation for clinical worsening of depression, suicidality, and unusual changes in behavior, especially during the first few months after antidepressant initiation or when the dose is adjusted. Family members and caregivers should be instructed to closely observe the patient (ie, daily) and communicate condition with healthcare provider. Patients should also be monitored for associated behaviors (eg, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania) which may increase the risk for worsening depression or suicidality. Worsening depression or emergence of suicidality (or associated behaviors listed above) that is abrupt in onset, severe, or not part of the presenting symptoms, may require discontinuation or modification of drug therapy. SSRI-associated behavioral activation (ie, restlessness, hyperkinesis, hyperactivity, agitation) is two- to threefold more prevalent in children compared to adolescents; it is more prevalent in adolescents compared to adults. Somnolence (including sedation and drowsiness) is more common in adults compared to children and adolescents (Safer, 2006).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Avoid abrupt discontinuation; discontinuation symptoms (including agitation, dysphoria, anxiety, confusion, dizziness, hypomania, nightmares, and other symptoms) may occur if therapy is abruptly discontinued or dose reduced; taper the dose to minimize risks of discontinuation symptoms; if intolerable symptoms occur following a decrease in dosage or upon discontinuation of therapy, consider resuming the previous dose with a more gradual taper.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     To reduce risk of intentional overdose, write prescriptions for the smallest quantity consistent with good patient care. Screen individuals for bipolar disorder prior to treatment (using antidepressants alone may induce manic episodes in patients with this condition). Potentially fatal serotonin syndrome may occur when SSRIs are used in combination with serotonergic drugs (eg, triptans) or drugs that impair the metabolism of serotonin (eg, MAO inhibitors).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Dropper for oral concentrate contains natural rubber latex which may cause allergic reactions in susceptible individuals; avoid use in patients with allergy to latex. Some tablets contain polysorbate 80 (Tween 80) which may cause allergic reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F220720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2B6 (moderate), CYP2C19 (moderate), CYP2C8 (weak), CYP2C9 (weak), CYP2D6 (moderate), CYP3A4 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F220651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Management: Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol.  Monitor for increased psychomotor impairment in patients who consume alcohol during treatment with selective serotonin reuptake inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Acebutolol; Atenolol; Betaxolol (Ophthalmic); Betaxolol (Systemic); Bisoprolol; Carteolol (Ophthalmic); Esmolol; Labetalol; Levobunolol; Metipranolol; Nadolol; Penbutolol; Sotalol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2, 2C, and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CloZAPine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inhibitors (Moderate) may decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproheptadine: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May decrease the serum concentration of Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextromethorphan: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan.  Management: Avoid the concurrent use of dextromethorphan and SSRIs, particularly fluoxetine and paroxetine, when possible.  The risk for this interaction may persist for several weeks following discontinuation of fluoxetine or paroxetine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May enhance the adverse/toxic effect of Sertraline. This is specifically related to sertraline oral concentrate due to its alcohol content (12%). Management: Sertraline Oral Concentrate contains 12% alcohol, and its use should be avoided with disulfiram.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Sertraline. Sertraline may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Galantamine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Galantamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents.  Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Selective Serotonin Reuptake Inhibitors may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Selective Serotonin Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could increase the risk of serotonin toxicity/serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Methadone. Fluvoxamine appears to be the only interacting SSRI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with selective serotonin reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor). NSAID (COX-2 Inhibitor) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.  Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Sertraline. Sertraline may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RisperiDONE: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of RisperiDONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tryptophan: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1055437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tryptophan supplements may increase serious side effects; its use is",
"     <b>",
"      not recommended",
"     </b>",
"     . Grapefruit juice may significantly increase sertraline serum concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablets: Food may slightly increase AUC, increase peak concentrations by 25% and shorten the time to peak plasma concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral concentrate: Food may prolong the rate, but does not effect the extent of absorption",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F220653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F220669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. Sertraline crosses the human placenta. An increased risk of teratogenic effects, including cardiovascular defects, may be associated with maternal use of sertraline or other SSRIs; however, available information is conflicting. Nonteratogenic effects in the newborn following SSRI/SNRI exposure late in the third trimester include respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypo- or hypertonia, hyper-reflexia, jitteriness, irritability, constant crying, and tremor. Symptoms may be due to the toxicity of the SSRIs/SNRIs or a discontinuation syndrome and may be consistent with serotonin syndrome associated with SSRI treatment. Persistent pulmonary hypertension of the newborn (PPHN) has also been reported with SSRI exposure. The long-term effects of",
"     <i>",
"      in utero",
"     </i>",
"     SSRI exposure on infant development and behavior are not known.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to pregnancy-induced physiologic changes, women who are pregnant may require adjusted doses of sertraline to achieve euthymia. The ACOG recommends that therapy with SSRIs or SNRIs during pregnancy be individualized; treatment of depression during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary healthcare provider, and pediatrician. According to the American Psychiatric Association (APA), the risks of medication treatment should be weighed against other treatment options and untreated depression. For women who discontinue antidepressant medications during pregnancy and who may be at high risk for postpartum depression, the medications can be restarted following delivery. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1055425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Weight and growth in children if long-term therapy; uric acid, CBC, liver function, serum sodium, urine output. Monitor patient periodically for symptom resolution; monitor for worsening depression, suicidality, and associated behaviors (especially at the beginning of therapy or when doses are increased or decreased)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1055415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective inhibitor of CNS neuronal serotonin uptake; minimal effects on reuptake of norepinephrine or dopamine; does not significantly bind to alpha-adrenergic, benzodiazepine, cholinergic, dopamine, GABA, histamine, or serotonin receptors; may therefore be useful in patients at risk from sedation, hypotension and anticholinergic effects of tricyclic antidepressants; does not inhibit monoamine oxidase",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1055432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maximum effect may take several weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1055433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Significant first pass effect; undergoes N-demethylation to N-desmethylsertraline (significantly less active than sertraline); both parent and metabolite undergo oxidative deamination, followed by reduction, hydroxylation and conjugation with glucuronide (",
"     <b>",
"      Note:",
"     </b>",
"     Children 6-17 years may metabolize sertraline slightly better than adults, as pediatric AUCs and peak concentrations were 22% lower than adults when adjusted for weight; however, lower doses are recommended for younger pediatric patients to avoid excessive drug levels)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Tablets approximately equal to oral solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Parent: Mean: 26 hours; metabolite (N-desmethylsertraline): 62-104  hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 6-12 years: Mean: 26.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 13-17 years: Mean: 27.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 18-45 years: Mean: 27.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 40% to 45% of dose eliminated in urine (none as unchanged drug); 40% to 45% eliminated in feces (12% to 14% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: May be decreased in patients with hepatic impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not likely to remove significant amount of drug due to large V",
"     <sub>",
"      d",
"     </sub>",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1055423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/43/23222?source=see_link\">",
"      see \"Sertraline: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the Patient Medication Guide that you receive with each prescription and refill of sertraline. An increased risk of suicidal thinking and behavior has been reported with the use of antidepressants in children, adolescents, and young adults (18-24 years of age). Notify physician if you feel depressed, have thoughts of suicide, or become more agitated or irritable. May cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth. Take as directed; do not alter dose or frequency without consulting prescriber; avoid abrupt discontinuation. Some medicines should not be taken with sertraline or should not be taken for a while after sertraline has been discontinued; report the use of other medications, nonprescription medications, and herbal or natural products to your physician and pharmacist; avoid alcohol, grapefruit juice, tryptophan supplements, and the herbal medicine St John's wort; avoid aspirin, NSAIDs, or other drugs that affect coagulation (may increase risks of bleeding).",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1055435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Two larger studies of children and adolescents with depression and obsessive-compulsive disorder utilized a forced upward dosage titration of sertraline to 200 mg/day; these studies conclude that the adult dosage titration regimen can be used in children &ge;6 years and adolescents (Alderman, 1998; March, 1998); however, other studies in adults (Fabre, 1995) demonstrate that lower sertraline doses (50 mg/day) are as effective as higher doses with fewer adverse effects and discontinuations of therapy. Further studies are needed in pediatric patients to identify optimal doses; clinically, doses should be individually titrated based on patient response and adverse effects.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     A recent report (Lake, 2000) describes 5 children (age 8-15 years) who developed epistaxis (n=4) or bruising (n=1) while receiving sertraline therapy. Another recent report describes the SSRI discontinuation syndrome in 6 children; the syndrome was similar to that reported in adults (Diler, 2002). Due to limited long-term studies, the clinical usefulness of sertraline should be periodically re-evaluated in patients receiving the drug for extended intervals; effects of long term use of sertraline on pediatric growth, development, and maturation have not been directly assessed.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Neonates born to women receiving SSRIs late during the third trimester may experience respiratory distress, apnea, cyanosis, temperature instability, vomiting, feeding difficulty, hypoglycemia, constant crying, irritability, hypotonia, hypertonia, hyper-reflexia, tremor, jitteriness, and seizures; these symptoms may be due to a direct toxic effect, withdrawal syndrome, or (in some cases) serotonin syndrome. Withdrawal symptoms occur in 30% of neonates exposed to SSRIs",
"     <i>",
"      in utero",
"     </i>",
"     ; monitor newborns for at least 48 hours after birth; long-term effects of",
"     <i>",
"      in utero",
"     </i>",
"     exposure to SSRIs are unknown (Levinson-Castiel, 2006).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alderman J, Wolkow R, Chung M, et al, &ldquo;Sertraline Treatment of Children and Adolescents With Obsessive-Compulsive Disorder or Depression: Pharmacokinetics, Tolerability, and Efficacy,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1998, 37(4):386-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/18/7465/abstract-text/9549959/pubmed\" id=\"9549959\" target=\"_blank\">",
"        9549959",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ambrosini PJ, Wagner KD, Biederman J, et al, &ldquo;Multicenter Open-Label Sertraline Study in Adolescent Outpatients With Major Depression,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1999, 38(5):566-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/18/7465/abstract-text/10230188/pubmed\" id=\"10230188\" target=\"_blank\">",
"        10230188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al, &ldquo;Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(6):579-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/18/7465/abstract-text/16467545 /pubmed\" id=\"16467545 \" target=\"_blank\">",
"        16467545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Diler R and Avci A, &ldquo;Selective Serotonin Reuptake Inhibitor Discontinuation Syndrome in Children: Six Case Reports,&rdquo;",
"      <i>",
"       Current Therapeutic Research",
"      </i>",
"      , 2002, 63(3):188-97.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dopheide JA, \"Recognizing and Treating Depression in Children and Adolescents,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2006, 63(3):233-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/18/7465/abstract-text/16434782 /pubmed\" id=\"16434782 \" target=\"_blank\">",
"        16434782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fabre LF, Abuzzahab FS, Amin M, et al, &ldquo;Sertraline Safety and Efficacy in Major Depression: A Double-Blind Fixed-Dose Comparison With Placebo,&rdquo;",
"      <i>",
"       Biol Psychiatry",
"      </i>",
"      , 1995, 38(9):592-602.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/18/7465/abstract-text/8573661 /pubmed\" id=\"8573661 \" target=\"_blank\">",
"        8573661",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Findling RL, Reed MD, and Blumer JL, &ldquo;Pharmacological Treatment of Depression in Children and Adolescents,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 1999, 1(3):161-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/18/7465/abstract-text/10937449 /pubmed\" id=\"10937449 \" target=\"_blank\">",
"        10937449",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lake MB, Birmaher B, Wassick S, et al, &ldquo;Bleeding and Selective Serotonin Reuptake Inhibitors in Childhood and Adolescence,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2000, 10(1):35-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/18/7465/abstract-text/10755580/pubmed\" id=\"10755580\" target=\"_blank\">",
"        10755580",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levinson-Castiel R, Merlob P, Linder N, et al, \"Neonatal Abstinence Syndrome After",
"      <i>",
"       in utero",
"      </i>",
"      Exposure to Selective Serotonin Reuptake Inhibitors in Term Infants,\"",
"      <i>",
"       Arch Pediatr Adolesc Med",
"      </i>",
"      , 2006, 160(2):173-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/18/7465/abstract-text/16461873/pubmed\" id=\"16461873\" target=\"_blank\">",
"        16461873",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      March JS, Biederman J, Wolkow R, et al, &ldquo;Sertraline in Children and Adolescents With Obsessive-Compulsive Disorder: A Multicenter Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 280(20):1752-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/18/7465/abstract-text/9842950/pubmed\" id=\"9842950\" target=\"_blank\">",
"        9842950",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McConville BJ, Minnery KL, Sorter MT, et al, &ldquo;An Open Study of the Effects of Sertraline on Adolescent Major Depression,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 1996, 6(1):41-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/18/7465/abstract-text/9231298/pubmed\" id=\"9231298\" target=\"_blank\">",
"        9231298",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Safer DJ and Zito JM, \"Treatment Emergent Adverse Effects of Selective Serotonin Reuptake Inhibitors by Age Group: Children vs. Adolescents,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2006, 16(1/2):159-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/18/7465/abstract-text/16553536/pubmed\" id=\"16553536\" target=\"_blank\">",
"        16553536",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sharp SC and Hellings JA, \"Efficacy and Safety of Selective Serotonin Reuptake Inhibitors in the Treatment of Depression in Children and Adolescents: Practitioner Review,\"",
"      <i>",
"       Clin Drug Investig",
"      </i>",
"      , 2006, 26(5):247-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/18/7465/abstract-text/17163258/pubmed\" id=\"17163258\" target=\"_blank\">",
"        17163258",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thomsen PH, &ldquo;Obsessive-Compulsive Disorder: Pharmacological Treatment,&rdquo;",
"      <i>",
"       Eur Child Adolesc Psychiatry",
"      </i>",
"      , 2000, 9 (Suppl 1):I76-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/18/7465/abstract-text/11140782 /pubmed\" id=\"11140782 \" target=\"_blank\">",
"        11140782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tierney E, Joshi PT, Llinas JF, et al, &ldquo;Sertraline for Major Depression in Children and Adolescents: Preliminary Clinical Experience,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 1995; 5(1):13-27.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wagner KD, \"Pharmacotherapy for Major Depression in Children and Adolescents,\"",
"      <i>",
"       Prog Neuropsychopharmacol Biol Psychiatry",
"      </i>",
"      , 2005, 29(5):819-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/18/7465/abstract-text/15908090/pubmed\" id=\"15908090\" target=\"_blank\">",
"        15908090",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12787 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.69.132.100-0D12DA5E94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_18_7465=[""].join("\n");
var outline_f7_18_7465=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709410\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220684\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220685\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055426\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055418\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220658\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220642\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874831\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055430\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055421\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055429\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220738\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220735\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055434\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055417\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055416\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220720\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220651\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055437\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220653\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220669\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055425\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055415\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055432\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055433\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055423\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055435\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12787\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12787|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=related_link\">",
"      Sertraline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/43/23222?source=related_link\">",
"      Sertraline: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_18_7466="Cyanide poisoning";
var content_f7_18_7466=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cyanide poisoning",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/18/7466/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/18/7466/contributors\">",
"     Shoma Desai, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/18/7466/contributors\">",
"     Mark Su, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/18/7466/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/18/7466/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/18/7466/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/18/7466/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/18/7466/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyanide is a mitochondrial toxin that is among the most rapidly lethal poisons known to man. Used in both ancient and modern times as a method of execution, cyanide causes death within minutes to hours of exposure. Though significant cyanide poisoning is uncommon, it must be recognized rapidly to ensure prompt administration of life-saving treatment. A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef65052 \" href=\"UTD.htm?25/15/25853\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic review will discuss the toxicity and management of cyanide poisoning. A general approach to the poisoned patient is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the Toxic Exposure Surveillance System, there were 3165 human exposures to cyanide from 1993 to 2002. Of these, 2.5 percent were fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/1\">",
"     1",
"    </a>",
"    ]. Cyanide poisoning may result from a broad range of exposures (",
"    <a class=\"graphic graphic_table graphicRef76365 \" href=\"UTD.htm?15/39/15996\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fire &ndash; In industrialized countries, the most common cause of cyanide poisoning is domestic fires [",
"      <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/2\">",
"       2",
"      </a>",
"      ]. Cyanide can be liberated during the combustion of products containing both carbon and nitrogen. These products include wool, silk, polyurethane",
"      <span class=\"nowrap\">",
"       (insulation/upholstery),",
"      </span>",
"      polyacrylonitriles (plastics), melamine resins (household goods), and synthetic rubber [",
"      <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/3-5\">",
"       3-5",
"      </a>",
"      ]. Vehicular fires can also expose victims to cyanide. Toxicologic evaluation of passengers following the explosion in 1985 of a Boeing 737 during take-off in Manchester, England, revealed that 20 percent of the 137 victims who escaped had dangerously elevated levels of carbon monoxide, while 90 percent had dangerously elevated levels of cyanide [",
"      <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/6\">",
"       6",
"      </a>",
"      ]. Overall, it is reported that significant levels of cyanide are present in up to 35 percent of all fire victims [",
"      <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Industrial &ndash; Worldwide industrial consumption of cyanide is estimated to be 1.5 million tons per year, and occupational exposures account for a significant number of cyanide poisonings [",
"      <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/8\">",
"       8",
"      </a>",
"      ]. Metal extraction in mining, electroplating in jewelry production, photography, plastics and rubber manufacturing, hair removal from hides, and rodent pesticide and fumigants have all been implicated in cyanide poisonings. Skin contact with cyanide salts can result in burns, which allow for enhanced absorption of cyanide through the skin. The combination of cyanide salts and acid, as utilized in electroplating, results in the release of cyanide gas, which can lead to lethal inhalational exposures. Splashes of cyanide solutions can result in skin as well as mucosal absorption [",
"      <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/2,9\">",
"       2,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Medical &ndash; Cyanide exposures can result from alternative and standard medical treatments. Amygdalin (trade name Laetrile), a substance derived from apricot and peach kernels, and introduced as an antineoplastic agent in the 1950s, can cause severe cyanide toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/10-12\">",
"       10-12",
"      </a>",
"      ]. The drug is alleged to kill cancer cells selectively via its metabolite, hydrocyanic acid. Laetrile is available as a 500 mg oral tablet that contains 30 to 150 mg of amygdalin [",
"      <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/13\">",
"       13",
"      </a>",
"      ]. Intestinal beta-d-glucosidase digests the amygdalin, releasing hydrogen cyanide (HCN). This enzymatic reaction explains why only gastrointestinal exposure, in contrast to intravenous administration, results in toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/10\">",
"       10",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Sodium",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      , a medication used in the treatment of hypertensive emergencies, contains five cyanide groups per molecule. Toxic levels of cyanide may be reached in patients who receive prolonged infusions of sodium nitroprusside, in patients with chronic renal failure, or in pediatric patients [",
"      <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. Treatment for 3 to 10 hours with 5 to 10",
"      <span class=\"nowrap\">",
"       mcg/kg/min",
"      </span>",
"      has resulted in fatalities [",
"      <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/16\">",
"       16",
"      </a>",
"      ]. Methods for preventing nitroprusside-induced cyanide poisoning include using silver foil on IV tubing (preventing light from decomposing the nitroprusside molecule), using maximal infusion rates of 2",
"      <span class=\"nowrap\">",
"       mcg/kg/min,",
"      </span>",
"      and adding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"       sodium thiosulfate",
"      </a>",
"      to the nitroprusside solution [",
"      <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Diet &ndash; The family Rosaceae, which includes the bitter almond, cherry laurel, apricot, plum, peach, pear, and apple, is responsible for many reported cyanide poisonings. These foods all contain cyanogenic glycosides, such as amygdalin, in their pits and seeds. The common (ie, sweet) almond does not cause cyanide intoxication.",
"     </li>",
"     <li>",
"      Other &ndash; Miscellaneous exposure to cyanide may occur during illicit synthesis of phencyclidine, terrorist attacks, ingestion of acetonitrile (artificial nail polish remover), product tampering, and cigarette smoking. Because of the natural cyanide found in tobacco, cigarette smokers have more than 2.5 times the mean whole blood cyanide level of nonsmokers (",
"      <a class=\"graphic graphic_table graphicRef65052 \" href=\"UTD.htm?25/15/25853\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal cellular metabolism, most adenosine triphosphate (ATP) is generated from oxidative phosphorylation. An important part of this process is the shuttling of electrons through the mitochondrial cytochrome complex (also known as the electron transport chain) (",
"    <a class=\"graphic graphic_figure graphicRef78699 \" href=\"UTD.htm?25/5/25681\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Cyanide avidly binds to the ferric ion (Fe3+) of cytochrome oxidase a3, inhibiting this final enzyme in the mitochondrial cytochrome complex. When this enzyme's activity is blocked, oxidative phosphorylation ceases. The cell must then switch to anaerobic metabolism of glucose to generate ATP.",
"   </p>",
"   <p>",
"    Anaerobic metabolism leads to the formation of lactic acid and the development of metabolic acidosis. Hydrogen ions produced by ATP hydrolysis are no longer consumed in aerobic ATP production, exacerbating this acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/19\">",
"     19",
"    </a>",
"    ]. Serum bicarbonate decreases as it buffers excess acid, leading to an increased anion gap.",
"   </p>",
"   <p>",
"    Despite an ample oxygen supply, cells cannot utilize oxygen because of their poisoned electron transport chain. This \"functional\" or \"histotoxic\" hypoxia is particularly deleterious to the cardiovascular and central nervous systems (especially the basal ganglia).",
"   </p>",
"   <p>",
"    A number of other mechanisms may exacerbate brain injury. Cyanide's nonspecific inhibition of antioxidants (such as catalase, glutathione reductase, and superoxide dismutase) results in the accumulation of toxic oxygen free-radicals. Cyanide causes the release of glutamate, which causes detrimental stimulation of N-methyl-D-aspartate (NMDA) receptors. Cyanide also inhibits glutamic acid decarboxylase (GAD), the enzyme responsible for the formation of the inhibitory neurotransmitter gamma&ndash;aminobutyric acid (GABA) from glutamic acid. Consequently, cyanide reduces the seizure threshold as GABA levels fall [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although cyanide has a primary affinity for ferric (Fe3+) iron, a small amount may bind to the ferrous (Fe2+) iron of hemoglobin, forming cyanohemoglobin, which is unable to transport oxygen, thereby further exacerbating tissue hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     KINETICS AND METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyanide is rapidly absorbed through the respiratory tract and mucous membranes, and it can also be absorbed through the gastrointestinal tract and skin [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/22\">",
"     22",
"    </a>",
"    ]. Once absorbed, cyanide is quickly distributed in the body with an estimated volume of distribution of 1.5",
"    <span class=\"nowrap\">",
"     L/kg.",
"    </span>",
"    Approximately 60 percent is protein bound [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vivo, cyanide metabolism and neutralization involves a number of mechanisms. The most important is the detoxification of cyanide via the enzyme rhodanese. Rhodanese is found abundantly in many tissues, particularly the liver and muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/22\">",
"     22",
"    </a>",
"    ]. Thiosulfate is a sulfur donor in the reaction catalyzed by rhodanese that converts cyanide to thiocyanate, a water soluble molecule excreted in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A minor pathway for cyanide detoxification involves",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"     hydroxocobalamin",
"    </a>",
"    , the precursor to vitamin B12. Circulating hydroxocobalamin combines with cyanide to form cyanocobalamin, which is safely excreted in the urine. Finally, a small amount of unmetabolized cyanide is eliminated through urine, sweat, and expiration [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical features of cyanide poisoning are dependent upon the route, duration, and amount of exposure. Central nervous system and cardiovascular system dysfunction are most prominent. Symptoms and signs can include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Central nervous system &ndash; Headache, anxiety, confusion, vertigo, coma, seizures",
"     </li>",
"     <li>",
"      Cardiovascular &ndash; Initial tachycardia and hypertension, then bradycardia and hypotension, atrioventricular block, ventricular dysrhythmias [",
"      <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Respiratory &ndash; Initial tachypnea then bradypnea, pulmonary edema",
"     </li>",
"     <li>",
"      Gastrointestinal &ndash; Vomiting, abdominal pain",
"     </li>",
"     <li>",
"      Skin &ndash; Flushing (cherry-red color), cyanosis (late finding)",
"     </li>",
"     <li>",
"      Renal &ndash; Renal failure",
"     </li>",
"     <li>",
"      Hepatic &ndash; Hepatic necrosis",
"     </li>",
"     <li>",
"      Miscellaneous &ndash; Rhabdomyolysis, bright red venules seen on funduscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, because of the decreased utilization of oxygen by tissues, the venous oxyhemoglobin concentration will be high, making venous blood appear bright red. Therefore, despite hypotension, apnea,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bradycardia, the patient does not usually appear cyanotic in the setting of cyanide poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms depend on the route of cyanide poisoning. After inhaling hydrogen cyanide (HCN), the victim may detect a bitter, almond odor (discernible to approximately 60 percent of the population) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/24\">",
"     24",
"    </a>",
"    ]. Initially, inhalation of small amounts of HCN causes headache, anxiety, nausea, and a metallic taste [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/9\">",
"     9",
"    </a>",
"    ]. In contrast, cyanogen chloride (CNCl) exposure predominantly results in eye and mucous membrane irritation and then pulmonary symptoms, namely bronchorrhea, cough, and dyspnea [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/21\">",
"     21",
"    </a>",
"    ]. Inhalation of 100 ppm for 30 minutes or 300 ppm for five minutes is usually fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While toxicity from parenteral exposure begins within seconds, toxicity from ingestion or dermal exposure is delayed from minutes to hours, depending on the extent of exposure. Ingestion of cyanide salts results in gastric irritation, frequently causing vomiting and abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/16\">",
"     16",
"    </a>",
"    ]. The lethal oral dose is 50 mg of hydrogen cyanide (HCN) or 200 mg of potassium cyanide (KCN) in an adult [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/9,21\">",
"     9,21",
"    </a>",
"    ]. The lethal dermal exposure is estimated to be 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef52242 \" href=\"UTD.htm?4/17/4379\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Delayed sequelae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survivors of severe cyanide poisoning may develop delayed-onset Parkinsonism or other neurologic sequelae. The basal ganglia in particular are sensitive to cyanide toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/24\">",
"     24",
"    </a>",
"    ]. Basal ganglia injury may be due to either direct cellular injury or secondary hypoxic effects. Computed tomography (CT) and magnetic resonance imaging (MRI) of the brain may demonstrate radiologic changes several weeks after the exposure. Resolution of symptoms is variable, and treatment is supportive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Chronic cyanide exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic cyanide exposure results in vague symptoms, such as headache, dysgeusia (abnormal taste), vomiting, chest pain, abdominal pain, and anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/9\">",
"     9",
"    </a>",
"    ]. There are at least three insidious syndromes associated with chronic, low-level cyanide exposure: tobacco amblyopia, tropical ataxic neuropathy, and Leber hereditary neuropathy.",
"   </p>",
"   <p>",
"    Tobacco amblyopia occurs predominantly in male cigarette smokers and manifests as progressive visual loss. It may result from an inherent inability to detoxify cyanide, and symptoms may reverse following smoking cessation or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"     hydroxocobalamin",
"    </a>",
"    (Cyanokit&reg;) administration.",
"   </p>",
"   <p>",
"    Tropical ataxic neuropathy (TAN) is a demyelinating condition associated with excessive cassava consumption, usually in the poor and malnourished. The cassava plant contains a cyanogen, linamarin, which may not be removed with inadequate processing. Signs and symptoms of TAN include paresthesias, ataxia, hearing loss, and optic atrophy. Vitamin B12 deficiency may contribute to the condition. Cessation of dietary cassava and administration of vitamin B12 ameliorates symptoms.",
"   </p>",
"   <p>",
"    Leber's hereditary optic neuropathy is a rare, gradual loss of central vision that appears to be due to a defect in cyanide metabolism. A deficiency of rhodanese is one proposed mechanism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87269935\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87269998\">",
"    <span class=\"h2\">",
"     General testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratory evaluation in the potentially poisoned patient should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fingerstick glucose, to rule out hypoglycemia as the cause of any alteration in mental status",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      and salicylate levels, to rule out these common coingestions",
"     </li>",
"     <li>",
"      Electrocardiogram, to rule out conduction system poisoning by drugs that effect the QRS or QTc intervals",
"     </li>",
"     <li>",
"      Pregnancy test in women of childbearing age",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87270005\">",
"    <span class=\"h2\">",
"     Specific testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific testing in cases of potential cyanide poisoning should also include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basic chemistries (Na+, Cl-, K+, HCO3-) and arterial blood gas to assess for anion gap metabolic acidosis",
"     </li>",
"     <li>",
"      Serum lactate to confirm lactic acidosis",
"     </li>",
"     <li>",
"      Central venous blood gas, if possible, to assess venous-arterial PO2 gradient",
"     </li>",
"     <li>",
"      Carboxyhemoglobin and methemoglobin levels (measured by",
"      <strong>",
"       co-oximetry",
"      </strong>",
"      ), particularly if there is any concern for concomitant carbon monoxide exposure (eg, house or vehicle fire) or exposure to drugs that produce methemoglobinemia (",
"      <a class=\"graphic graphic_table graphicRef65052 \" href=\"UTD.htm?25/15/25853\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22790?source=see_link\">",
"       \"Smoke inhalation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87270012\">",
"    <span class=\"h3\">",
"     Anion gap acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A severe metabolic acidosis with an increased anion gap is expected in cyanide poisoning. In addition to its inhibitory effects on cellular respiration, cyanide can induce cardiovascular collapse and seizures, which exacerbate anion gap metabolic acidosis. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87270019\">",
"    <span class=\"h3\">",
"     Lactate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyanide-poisoned patients have an elevated serum lactate concentration. A retrospective study of 11 ICU patients with cyanide poisoning found that plasma lactate levels significantly correlated with blood cyanide [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/25\">",
"     25",
"    </a>",
"    ]. There were significant inverse correlations between lactate and systolic blood pressure, respiratory rate, and arterial pH. In fact, lactate levels of 10",
"    <span class=\"nowrap\">",
"     mmol/",
"    </span>",
"    L or greater have been shown to be both sensitive and specific for cyanide poisoning in smoke inhalation victims [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/26\">",
"     26",
"    </a>",
"    ]. Consequently, a normal serum lactate should lead the clinician to entertain other diagnoses. Serial lactate levels can be used to monitor the patient's progress during treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87270026\">",
"    <span class=\"h3\">",
"     Venous PO2",
"    </span>",
"    &nbsp;&mdash;&nbsp;A narrowing of the venous-arterial PO2 gradient (ie, venous hyperoxia) may be seen in the cyanide-poisoned patient [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/27\">",
"     27",
"    </a>",
"    ]. Cyanide inhibits cellular oxidative phosphorylation resulting in a marked decrease in peripheral tissue oxygen extraction from the blood. This results in elevated central venous oxygenation. On examination, the skin may appear flushed and the venules in the retina bright red. Laboratory evaluation may reveal a decreased arterial&ndash;venous oxygen gradient. Clinicians should keep in mind that a decreased oxygen gradient is nonspecific and can result from other inhibitors of oxidative phosphorylation, such as carbon monoxide, hydrogen sulfide, and azides.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87270033\">",
"    <span class=\"h3\">",
"     Cyanide level",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood cyanide levels may be obtained for diagnosis confirmation, but results are not available in time to be clinically useful. Antidotal treatment must be administered as soon as possible, based on the clinical presentation. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Antidotal treatment guidelines'",
"    </a>",
"    below.) Blood cyanide levels may also be unreliable, as testing requires proper storage conditions and must be prompt. Nonetheless, blood cyanide levels of 0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    correlate with",
"    <span class=\"nowrap\">",
"     tachycardia/flushing,",
"    </span>",
"    1 to 2.5",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    with obtundation, 2.5 to 3",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    with coma, and greater than 3",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    with death [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cyantesmo&reg; test strips are colorimetric strips used in the testing of waste water and during autopsies. One in vitro study assessed the ability of these strips to detect cyanide in simulated samples [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/28\">",
"     28",
"    </a>",
"    ] and found they were accurate only at markedly elevated cyanide levels. Additional work is needed before this test can be considered for routine clinical use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyanide poisoning is an uncommon entity. Therefore, making the diagnosis requires that the clinician maintain a high index of suspicion based on history and clinical presentation. Patients who are victims of fires or reported ingestions, are exposed at work, or have recently been treated with sodium",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    should all be considered potentially cyanide poisoned. When a clear history is unavailable, clinicians should consider any patient with altered mental status and a metabolic acidosis of unknown etiology a possible cyanide poisoning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87269650\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbon monoxide poisoning is similar to cyanide in presentation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=see_link\">",
"     \"Carbon monoxide poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to cyanide's wide range of possible symptoms and signs, the clinician must consider a number of potential diagnoses, including those listed below. Generally, the diagnosis is made based on a history of exposure and a consistent clinical presentation, since very few of these intoxicants have a rapidly available diagnostic test. If the diagnosis is in doubt, clinicians should seek assistance from a medical toxicologist or regional poison center. (See",
"    <a class=\"local\" href=\"#H106424559\">",
"     'Additional resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A patient with altered mental status, seizures, hypotension, and lactic acidosis may be poisoned with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tricyclic antidepressants (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36231?source=see_link\">",
"       \"Tricyclic antidepressant poisoning\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       Isoniazid",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19142?source=see_link\">",
"       \"Isoniazid: An overview\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Organophosphates (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33176?source=see_link\">",
"       \"Organophosphate and carbamate poisoning\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Salicylates (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19913?source=see_link\">",
"       \"Salicylate (aspirin) poisoning in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Methemoglobin producing agents (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=see_link\">",
"       \"Clinical features, diagnosis, and treatment of methemoglobinemia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Strychnine (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/5/40022?source=see_link\">",
"       \"Strychnine poisoning\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A patient who suddenly collapsed after exposure to a gas may be poisoned with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carbon monoxide (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=see_link\">",
"       \"Carbon monoxide poisoning\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hydrogen sulfide gas",
"     </li>",
"     <li>",
"      Phosphine",
"     </li>",
"     <li>",
"      Arsine (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/20/8521?source=see_link\">",
"       \"Chemical terrorism: Diagnosis and treatment of exposure to chemical weapons\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Asphyxiants (eg, methane)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Also, exposure to cyanogen chloride can mimic exposure to any chemical irritant (eg, chlorine) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Untreated, cyanide poisoning is rapidly lethal. If clinical history and examination are suggestive of cyanide poisoning, antidotal therapy must be given immediately, barring any contraindications. Management should also include resuscitation and decontamination. A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef76365 \" href=\"UTD.htm?15/39/15996\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Antidotal treatment guidelines'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Clinicians should seek assistance from a medical toxicologist or a regional poison center. (See",
"    <a class=\"local\" href=\"#H106424559\">",
"     'Additional resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Resuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;First, clinicians must stabilize the patient's airway, breathing, and circulation. The patient's airway should be secured as necessary and high-flow oxygen should be given, regardless of pulse oximetry readings. Mouth-to-mouth resuscitation is contraindicated in cyanide poisoning due to the risk of exposure to the provider of cardiopulmonary resuscitation (CPR) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/16\">",
"     16",
"    </a>",
"    ]. Otherwise, CPR should be provided as per advanced cardiac life support protocols. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dextrose, thiamine, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    can be given to unresponsive patients. Seizures should be treated with benzodiazepines. Hypotension should be treated with fluids and vasopressors as needed. Comorbid conditions and concurrent exposures are treated as necessary. A detailed discussion of general management of the poisoned patient is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients poisoned by cyanide through inhalation or topical exposure must be rapidly removed from the source, and their clothing taken off and appropriately discarded. In dermal exposures, wounds must be cleansed with soap and water to prevent further absorption. Rescuers should wear protective suits and respirators until proper decontamination is completed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gastrointestinal decontamination should be performed rapidly in cases of oral ingestion, as cyanide is quickly absorbed. A single dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC) should be administered (50 g in adults; 1",
"    <span class=\"nowrap\">",
"     g/kg,",
"    </span>",
"    up to 50 g maximum, in children). There is no role for multiple doses of AC or cathartics, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39140?source=see_link\">",
"     magnesium citrate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    . Charcoal should be withheld in nonintubated patients with a depressed mental status. While laboratory studies have demonstrated that cyanide binds poorly to AC, animal studies have shown decreased mortality among rats receiving AC after lethal potassium cyanide ingestions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link\">",
"     \"Gastrointestinal decontamination of poisoned adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Orogastric lavage is not recommended. It may be attempted only if ingestion occurred within 60 minutes of presentation and a large amount of cyanide is thought to be present in the upper gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Antidotes",
"    </span>",
"    &nbsp;&mdash;&nbsp;If clinical history and examination are suggestive of cyanide poisoning, antidotal therapy must be given immediately, barring any contraindications. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Antidotal treatment guidelines'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Antidotal treatment of cyanide poisoning involves three strategies: binding of cyanide, induction of methemoglobinemia, and use of sulfur donors. In Europe, the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"     sodium thiosulfate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"     hydroxocobalamin",
"    </a>",
"    has provided successful treatment of severe poisoning. In the United States, the Cyanide Antidote Package (currently produced by Akorn Pharmaceuticals) may still be used in some locations to provide the cyanide antidotes if hydroxocobalamin is not available. It includes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/1/33813?source=see_link\">",
"     amyl nitrite",
"    </a>",
"    (12 0.3 mL ampules) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=see_link\">",
"     sodium nitrite",
"    </a>",
"    (two 300",
"    <span class=\"nowrap\">",
"     mg/10",
"    </span>",
"    mL ampules) to induce methemoglobinemia, and sodium thiosulfate (two 12.5",
"    <span class=\"nowrap\">",
"     g/50",
"    </span>",
"    mL vials) to act as a sulfur donor. The kit is designed to treat two adult patients or one adult patient twice.",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/1/33813?source=see_link\">",
"     amyl nitrite",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=see_link\">",
"     sodium nitrite",
"    </a>",
"    is",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in cases of concurrent carbon monoxide toxicity (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Induction of methemoglobinemia'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Direct cyanide binding",
"    </span>",
"    &nbsp;&mdash;&nbsp;One strategy in cyanide neutralization involves direct binding of cyanide, preferably using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"     hydroxocobalamin",
"    </a>",
"    (Cyanokit&reg;). Dicobalt edetate also binds cyanide but can cause severe side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12183682\">",
"    <span class=\"h4\">",
"     Hydroxocobalamin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"     Hydroxocobalamin",
"    </a>",
"    , a precursor of vitamin B12, contains a cobalt moiety that avidly binds to intracellular cyanide (with greater affinity than cytochrome oxidase) forming cyanocobalamin [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/32\">",
"     32",
"    </a>",
"    ]. This molecule is stable, with few side effects, and is readily excreted in the urine.",
"   </p>",
"   <p>",
"    The dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"     hydroxocobalamin",
"    </a>",
"    is 70",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (typical adult dose is 5 g) given intravenously (IV). This dose is effective for the majority of adult patients. A second half-dose may be given depending upon the severity of poisoning or the clinical response to treatment. Although optimum pediatric dosing is not well established, some recommend 70",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV (maximum dose 5 g) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/21\">",
"     21",
"    </a>",
"    ]. The half-life is 24 to 48 hours.",
"   </p>",
"   <p>",
"    In France,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"     hydroxocobalamin",
"    </a>",
"    is commonly used in conjunction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"     sodium thiosulfate",
"    </a>",
"    , a combination shown to be effective and safe in severe cyanide poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/7,33-35\">",
"     7,33-35",
"    </a>",
"    ]. One study of heavy smokers found that hydroxocobalamin decreased cyanide levels by 59 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/36\">",
"     36",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"     Hydroxocobalamin",
"    </a>",
"    , when given at the recommended dose, may cause a temporary reddish discoloration of the skin, plasma, urine, and mucous membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. These changes last for approximately two to three days, altering the laboratory values of colorimetric tests (eg, serum creatinine, serum aspartate aminotransferase (AST), bilirubin, and magnesium) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Of note, IV infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"     hydroxocobalamin",
"    </a>",
"    appears to interfere with co-oximetry measurements of total hemoglobin, carboxyhemoglobin, methemoglobin, and oxyhemoglobin [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. This may complicate the assessment of smoke inhalation victims (who may suffer from both cyanide and carbon monoxide poisoning) if hydroxocobalamin is administered before blood is obtained for co-oximetry.",
"   </p>",
"   <p>",
"    In one study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"     hydroxocobalamin",
"    </a>",
"    dosing in adults, adverse effects from high doses included rash, headache, nausea, chest discomfort, decreased lymphocyte percentage, and dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/43\">",
"     43",
"    </a>",
"    ]. At the recommended dose, both transient hypertension and slowing of the heart rate have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/7,36,40\">",
"     7,36,40",
"    </a>",
"    ]. Overall, hydroxocobalamin is considered safe and effective [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/32,44\">",
"     32,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12183689\">",
"    <span class=\"h4\">",
"     Dicobalt edetate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dicobalt edetate is an intravenous chelator of cyanide, with a rapid onset of action, used in the United Kingdom. The dose is 20 mL of a 1.5 percent solution given over one minute. It is associated with multiple severe side effects including seizures, anaphylactic shock, hypotension, and cardiac dysrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/2\">",
"     2",
"    </a>",
"    ]. As a result, it is administered only when the diagnosis of cyanide is nearly certain and alternative treatments are unavailable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Induction of methemoglobinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another antidotal strategy involves the induction of methemoglobin. The formation of methemoglobin entails the oxidation of the ferrous (Fe2+) moiety in hemoglobin to the ferric (Fe3+) form. This provides an attractive alternative binding site for cyanide, in direct competition with the site on the cytochrome complex. When cyanide binds methemoglobin, a relatively less toxic cyanomethemoglobin is formed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The induction of methemoglobinemia is accomplished by the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/1/33813?source=see_link\">",
"     amyl nitrite",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=see_link\">",
"     sodium nitrite",
"    </a>",
"    , or dimethylaminophenol. Amyl nitrite ampules are crushed and then inhaled by the patient (either from under the patient's nose or via the endotracheal tube) for 30 seconds of each minute. Thirty second pauses allow for adequate oxygenation during treatment. Amyl nitrite induces only a 5 percent methemoglobinemia, and is thus only a temporizing measure. It may be used when intravenous access is unavailable, such as in the prehospital setting [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=see_link\">",
"     Sodium nitrite",
"    </a>",
"    300 mg (or 10",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    is administered intravenously, inducing a 15 to 20 percent methemoglobinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/43\">",
"     43",
"    </a>",
"    ]. This level of methemoglobinemia is easily tolerated by most patients. However, methemoglobin shifts the oxygen-hemoglobin dissociation curve to the left further hindering oxygen delivery to tissues (",
"    <a class=\"graphic graphic_figure graphicRef81216 \" href=\"UTD.htm?2/26/2479\">",
"     figure 2",
"    </a>",
"    ). A decreased dose is required for children weighing less than 25 kg and patients with anemia. A 20 to 30 percent level of methemoglobinemia, the goal of cyanide treatment in the average adult patient, may be lethal in children or anemic patients, who have little reserve.",
"   </p>",
"   <p>",
"    The appropriate dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=see_link\">",
"     sodium nitrite",
"    </a>",
"    given to adult patients incapable of tolerating significant methemoglobinemia is adjusted according to the patient's hemoglobin. A medical toxicologist or regional poison center should be consulted for appropriate dosing. Approximate initial dosing is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemoglobin 7",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      dose is 0.19",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of 3 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=see_link\">",
"       sodium nitrite",
"      </a>",
"     </li>",
"     <li>",
"      Hemoglobin 8",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      dose is 0.22",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of 3 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=see_link\">",
"       sodium nitrite",
"      </a>",
"     </li>",
"     <li>",
"      Hemoglobin 9",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      dose is 0.25",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of 3 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=see_link\">",
"       sodium nitrite",
"      </a>",
"     </li>",
"     <li>",
"      Hemoglobin 10",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      dose is 0.27",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of 3 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=see_link\">",
"       sodium nitrite",
"      </a>",
"     </li>",
"     <li>",
"      Hemoglobin 11",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      dose is 0.30",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of 3 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=see_link\">",
"       sodium nitrite",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients receiving nitrites may develop hypotension and tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/16\">",
"     16",
"    </a>",
"    ]. Arthralgias, myalgias, vomiting, and psychosis may also occur. Nitrites should be avoided in pregnant women.",
"   </p>",
"   <p>",
"    In addition to inducing a methemoglobinemia, nitrites may provide benefit by causing vasodilation. Nitrites release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    , a vasodilator, leading to increased blood flow to the liver and other organs, thereby enhancing the metabolism of cyanide. This proposed effect is supported by the success of other vasodilators in protecting the body from cyanide toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/21,45\">",
"     21,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dimethylaminophenol (4-DMAP), an agent introduced in Germany, is another inducer of methemoglobin. 4-DMAP is given in a dose of 5 mL of a 5 percent solution IV over one minute. It is potent and rapidly acting, achieving peak levels of methemoglobin within five minutes of administration. The potency of 4-DMAP, which can require",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    to reverse the extent of methemoglobinemia, is problematic. Methylene blue, the recommended reversal agent for methemoglobinemia, should be avoided in the setting of cyanide poisoning because its use can release free cyanide [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/46\">",
"     46",
"    </a>",
"    ]. Other potential adverse effects of 4-DMAP include reticulocytosis, nephrotoxicity, and hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of methemoglobinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of special note, patients who are victims of fires may be suffering from both carbon monoxide and cyanide toxicity. Carboxyhemoglobin causes the oxygen-hemoglobin dissociation curve to be shifted to the left creating tissue hypoxia. In these patients, the induction of methemoglobinemia could be lethal [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22790?source=see_link\">",
"     \"Smoke inhalation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=see_link\">",
"     \"Carbon monoxide poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Sulfur donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A third antidotal strategy involves maximizing the availability of sulfur donors for rhodanese, a ubiquitous enzyme that detoxifies cyanide by transforming it to thiocyanate. Thiocyanate is then renally excreted.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"     Sodium thiosulfate",
"    </a>",
"    is the therapeutic sulfur donor of choice.",
"   </p>",
"   <p>",
"    In theory, a 3:1 ratio of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"     sodium thiosulfate",
"    </a>",
"    to cyanide is required for complete detoxification. The recommended dose is 50 mL of a 25 percent solution (12.5 g) or 1.65",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    intravenously (",
"    <a class=\"graphic graphic_table graphicRef52242 \" href=\"UTD.htm?4/17/4379\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/16,21\">",
"     16,21",
"    </a>",
"    ]. The onset of action may be slow (up to 30 minutes). Because thiocyanate levels of 10",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or higher may cause psychosis, arthralgias, vomiting, and myalgias, patients with renal failure may require hemodialysis to remove it from the blood stream [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/7\">",
"     7",
"    </a>",
"    ]. However, in most patients sodium thiosulfate is safe and well tolerated.",
"   </p>",
"   <p>",
"    In an animal experiment, nitrite treatment alone tripled the dose of cyanide needed to cause death, while thiosulfate treatment alone quadrupled the dose. In combination, however, nitrites and thiosulfate increased the dose of cyanide required to cause death 13-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/21\">",
"     21",
"    </a>",
"    ], suggesting synergy between the two treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6019904\">",
"    <span class=\"h3\">",
"     Hyperbaric oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of two animal studies suggest that hyperbaric oxygen (HBO), used in combination with antidotal therapy, is an effective treatment for cyanide toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. One study found that HBO may facilitate transport of cyanide from tissue to blood, theoretically enhancing detoxification [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/48\">",
"     48",
"    </a>",
"    ]. The other reported improved respiratory status and a decreased surge in brain lactate with HBO therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/49\">",
"     49",
"    </a>",
"    ]. Further research and controlled studies in humans are needed to confirm these initial findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Antidotal treatment guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyanide poisoning is rare, but when present requires decisive action. We recommend treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"     sodium thiosulfate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"     hydroxocobalamin",
"    </a>",
"    when available. In hospitals without hydroxocobalamin, treatment with nitrites may be life-saving, but induction of 20 to 30 percent methemoglobinemia in a patient who is critically ill from another cause may prove catastrophic. When the history strongly suggests cyanide toxicity, we recommend prompt treatment with both nitrites and sodium thiosulfate. In such cases, the benefits of therapy outweigh the risks of methemoglobinemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Probable cyanide intoxication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Availability of treatment varies by region and hospital. Immediately below is a series of antidotal management recommendations, based upon treatment availability, for patients with",
"    <strong>",
"     probable",
"    </strong>",
"    cyanide intoxication:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients in countries where",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"       hydroxocobalamin",
"      </a>",
"      is available, it is the preferred treatment and we recommend:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"       Sodium thiosulfate",
"      </a>",
"      25 percent, 1.65",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      IV",
"      <strong>",
"       AND",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"       Hydroxocobalamin",
"      </a>",
"      70",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV (5 g is the standard adult dose)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients without contraindication to nitrites, in countries where",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"       hydroxocobalamin",
"      </a>",
"      is not available, we recommend the Akorn Cyanide Antidote Package, if available, which consists of the following three medications:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/1/33813?source=see_link\">",
"       Amyl nitrite",
"      </a>",
"      inhaled by the patient (held under the patient's nose or via the endotracheal tube) for 30 seconds of each minute, for three minutes",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=see_link\">",
"       Sodium nitrite",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV",
"      <strong>",
"       AND",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"       Sodium thiosulfate",
"      </a>",
"      (25 percent) 1.65",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      IV",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with contraindications to nitrites or with smoke inhalation (pending test results for carboxyhemoglobin), in countries where",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"       hydroxocobalamin",
"      </a>",
"      is not available, we recommend:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"       Sodium thiosulfate",
"      </a>",
"      (25 percent) 1.65",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      IV only",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In countries where 4-dimethylaminophenol (4-DMAP) or dicobalt edetate is available, and there are no contraindications to either drug, and neither",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"       hydroxocobalamin",
"      </a>",
"      nor the Akorn Antidote Package is available, we recommend:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      4-DMAP (5 percent) 5 mL IV over one minute OR",
"     </li>",
"     <li>",
"      If 4-DMAP is unavailable and the diagnosis is clear, dicobalt edetate (1.5 percent) 20 mL IV over one minute,",
"      <strong>",
"       ONLY",
"      </strong>",
"      if cyanide poisoning is highly suspected or confirmed",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Questionable cyanide intoxication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediately below is a series of antidotal management recommendations, based on treatment availability, for patients with",
"    <strong>",
"     questionable",
"    </strong>",
"    cyanide intoxication:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients in countries where",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"       hydroxocobalamin",
"      </a>",
"      is available, we recommend:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"       Sodium thiosulfate",
"      </a>",
"      (25 percent) 1.65",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      IV",
"      <strong>",
"       AND",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"       Hydroxocobalamin",
"      </a>",
"      70",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV (5 g is the standard adult dose)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients in countries where",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"       hydroxocobalamin",
"      </a>",
"      is not available, but the Akorn Cyanide Antidote Package is available, we recommend:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"       Sodium thiosulfate",
"      </a>",
"      (25 percent) 1.65",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      IV",
"      <strong>",
"       without",
"      </strong>",
"      the use of nitrites",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"     sodium thiosulfate",
"    </a>",
"    is administered, further testing (eg, mixed central venous oxygen saturation, blood gas analysis, and co-oximetry for carboxyhemoglobinemia and methemoglobinemia) should be obtained promptly. If ancillary data strongly support cyanide toxicity and rule out other potential causes of the patient's symptoms, we recommend the administration of nitrites as described above. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Probable cyanide intoxication'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Empiric treatment for smoke inhalation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should consider the possibility of cyanide toxicity and maintain a low threshold for initiating treatment in victims of smoke inhalation. Frequently, victims of house fires have a depressed level of consciousness, which may be caused by cyanide, carbon monoxide, other inhaled or ingested toxins, traumatic shock, or head injury. The pathophysiology and general management of smoke inhalation is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22790?source=see_link\">",
"     \"Smoke inhalation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest empiric treatment for cyanide toxicity be initiated in victims of smoke inhalation with an unexplained lactic acidosis or a low or declining end-tidal CO2 (EtCO2) level. If these measurements are unavailable, we suggest treatment be initiated in any patient demonstrating a depressed level of consciousness, cardiac arrest, or cardiac decompensation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest the following antidotal treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"       Sodium thiosulfate",
"      </a>",
"      (25 percent) 1.65",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      IV",
"      <strong>",
"       AND",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"       Hydroxocobalamin",
"      </a>",
"      70",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV (5 g is the standard adult dose)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/1/33813?source=see_link\">",
"     amyl nitrite",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=see_link\">",
"     sodium nitrite",
"    </a>",
"    is",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in cases of potential carbon monoxide toxicity (eg, from a fire), until carbon monoxide toxicity has been excluded.",
"   </p>",
"   <p>",
"    Serum lactate and EtCO2 monitoring may provide useful information when determining management of smoke inhalation victims. Cyanide toxicity poisons mitochondria, forcing cells to use anaerobic metabolism. This results in a lactic acidosis and a compensatory drop in EtCO2. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     PEDIATRIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology and clinical manifestations of acute cyanide for children and adults are similar [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5\">",
"     'Clinical presentation'",
"    </a>",
"    above.)&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"     Hydroxocobalamin",
"    </a>",
"    , the preferred treatment for cyanide intoxication, is considered safe in children. Although optimum pediatric dosing is not well established, some recommend 70",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major concern in pediatric patients with cyanide poisoning involves management using the Akorn Cyanide Antidote Package, when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"     hydroxocobalamin",
"    </a>",
"    is unavailable.",
"   </p>",
"   <p>",
"    In order to avoid dangerously high methemoglobin levels,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=see_link\">",
"     sodium nitrite",
"    </a>",
"    should be dosed according to the patient's hemoglobin. A medical toxicologist or regional poison center should be consulted for dosing details and assistance with management. The approximate initial dose of sodium nitrite, to be given no faster than 5",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    is as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemoglobin 7",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      dose is 0.19",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of 3 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=see_link\">",
"       sodium nitrite",
"      </a>",
"     </li>",
"     <li>",
"      Hemoglobin 8",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      dose is 0.22",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of 3 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=see_link\">",
"       sodium nitrite",
"      </a>",
"     </li>",
"     <li>",
"      Hemoglobin 9",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      dose is 0.25",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of 3 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=see_link\">",
"       sodium nitrite",
"      </a>",
"     </li>",
"     <li>",
"      Hemoglobin 10",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      dose is 0.27",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of 3 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=see_link\">",
"       sodium nitrite",
"      </a>",
"     </li>",
"     <li>",
"      Hemoglobin 11",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      dose is 0.30",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of 3 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=see_link\">",
"       sodium nitrite",
"      </a>",
"     </li>",
"     <li>",
"      Hemoglobin 12",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      dose is 0.33",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of 3 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=see_link\">",
"       sodium nitrite",
"      </a>",
"     </li>",
"     <li>",
"      Hemoglobin 13",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      dose is 0.36",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of 3 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=see_link\">",
"       sodium nitrite",
"      </a>",
"     </li>",
"     <li>",
"      Hemoglobin 14",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      dose is 0.39",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of 3 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=see_link\">",
"       sodium nitrite",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Point of care hemoglobin testing makes this approach easier to perform. In emergency departments where a rapid hemoglobin level is difficult to obtain, pediatric patients can be dosed on the basis of weight.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=see_link\">",
"     Sodium nitrite",
"    </a>",
"    is given 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV, or 0.33",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of a 3 percent solution IV. The dose should not exceed 10 mL and should not be given at a rate greater than 5",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    in order to avoid significant hypotension.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"     Sodium thiosulfate",
"    </a>",
"    is given IV 1.65",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of a 25 percent solution, up to a maximum of 12.5 g (50 mL). Sodium thiosulfate appears to cause fewer adverse effects than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=see_link\">",
"     sodium nitrite",
"    </a>",
"    and is considered safe for use in children [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/9,16\">",
"     9,16",
"    </a>",
"    ]. Gastrointestinal symptoms and localized burning at the injection site were noted in one volunteer study [",
"    <a class=\"abstract\" href=\"UTD.htm?7/18/7466/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106424559\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyanide is among the most rapidly lethal poisons known to man. A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef65052 \" href=\"UTD.htm?25/15/25853\">",
"     table 1",
"    </a>",
"    ). Clinicians should seek assistance from a medical toxicologist or a regional poison center. (See",
"    <a class=\"local\" href=\"#H106424559\">",
"     'Additional resources'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    Acute cyanide poisoning may result from a broad range of exposures (",
"    <a class=\"graphic graphic_table graphicRef76365 \" href=\"UTD.htm?15/39/15996\">",
"     table 2",
"    </a>",
"    ). In industrialized countries, the most common cause is domestic fires. Poisoning can also occur from industrial exposure (eg, mining, electroplating, plastic manufacturing), standard and alternative medical treatments (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    , laetrile), and certain foods (eg, Rosaceae family). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Cyanide toxicity occurs from cellular hypoxia, which results in an anion gap metabolic acidosis. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Clinical findings",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical features of cyanide poisoning are dependent upon the route, duration, and amount of exposure. Central nervous system and cardiovascular system dysfunction are most prominent. Symptoms and signs are described in detail above. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of the decreased utilization of oxygen by tissues, venous oxyhemoglobin concentration will be high, making venous blood appear bright red. Therefore, despite hypotension, apnea,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bradycardia, the patient does not appear cyanotic in the setting of cyanide poisoning. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Toxicity from parenteral exposure begins within seconds, toxicity from an ingestion or dermal exposure is delayed from minutes to hours (",
"      <a class=\"graphic graphic_table graphicRef52242 \" href=\"UTD.htm?4/17/4379\">",
"       table 3",
"      </a>",
"      ). Delayed and chronic sequelae are discussed above. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are victims of fires or reported ingestions, are exposed to cyanide at work, or have recently been treated with sodium",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      are all potentially cyanide poisoned. In the event that history is unavailable, clinicians should consider any patient with altered mental status and a metabolic acidosis of unknown etiology a possible cyanide poisoning. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Testing",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Routine laboratory evaluation in potential cyanide intoxication should include the following: fingerstick glucose,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      and salicylate levels, electrocardiogram, and a pregnancy test in women of childbearing age. (See",
"      <a class=\"local\" href=\"#H87269935\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific testing in potential cyanide intoxication should include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Basic chemistries (Na+, Cl-, K+, HCO3-) and arterial blood gas to assess for anion gap metabolic acidosis",
"     </li>",
"     <li>",
"      Serum lactate to confirm lactic acidosis and assess severity of exposure",
"     </li>",
"     <li>",
"      Central venous blood gas, if possible, to assess for a diminished venous-arterial PO2 gradient",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carboxyhemoglobin and methemoglobin levels (measured by",
"      <strong>",
"       co-oximetry",
"      </strong>",
"      ), particularly if there is any concern for concomitant carbon monoxide exposure (eg, house or vehicle fire) or exposure to drugs that produce methemoglobinemia (",
"      <a class=\"graphic graphic_table graphicRef51406 \" href=\"UTD.htm?38/28/39372\">",
"       table 4",
"      </a>",
"      ). IV infusion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"       hydroxocobalamin",
"      </a>",
"      may interfere with co-oximetry measurements of total hemoglobin, carboxyhemoglobin, methemoglobin, and oxyhemoglobin. (See",
"      <a class=\"local\" href=\"#H87269935\">",
"       'Laboratory evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22790?source=see_link\">",
"       \"Smoke inhalation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should seek assistance from a medical toxicologist or a regional poison center. (See",
"    <a class=\"local\" href=\"#H106424559\">",
"     'Additional resources'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinician's first responsibility is to stabilize the patient's airway, breathing, and circulation. Mouth-to-mouth resuscitation is",
"      <strong>",
"       contraindicated",
"      </strong>",
"      due to the potential for provider exposure. Otherwise, cardiopulmonary resuscitation should be provided as per advanced cardiac life support protocols. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"       \"Advanced cardiac life support (ACLS) in adults\"",
"      </a>",
"      .)&nbsp;(See",
"      <a class=\"local\" href=\"#H18\">",
"       'Resuscitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients poisoned by cyanide through inhalation or topical exposure must be rapidly removed from the source, and their clothing taken off and appropriately discarded. In dermal exposures, wounds must be cleansed with soap and water to prevent further absorption. Rescuers should wear protective suits and respirators until proper decontamination is completed.",
"     </li>",
"     <li>",
"      Gastrointestinal decontamination should be performed in cases of oral ingestion. Due to the rapid absorption of cyanide, oral decontamination should be performed rapidly. We recommend that a single dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"      (AC) be administered (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ); the typical dose is 50 g in adults and 1",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      in children. There is no role for multiple dose charcoal or charcoal cathartics, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39140?source=see_link\">",
"       magnesium citrate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"       sorbitol",
"      </a>",
"      . Charcoal should be withheld in patients who are sedated and may not be able to protect their airway, unless tracheal intubation is performed first. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link\">",
"       \"Gastrointestinal decontamination of poisoned adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antidotal treatment of cyanide poisoning involves three strategies: binding of cyanide, induction of methemoglobinemia, and use of sulfur donors. Each is described in the text. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Antidotes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Based upon treatment availability, we recommend the following approaches to antidotal therapy for patients with",
"      <strong>",
"       probable",
"      </strong>",
"      cyanide intoxication. Treatment for patients in whom cyanide poisoning is possible but unlikely is described in detail above. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Antidotal treatment guidelines'",
"      </a>",
"      above.):",
"     </li>",
"     <li>",
"      For patients in countries where",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"       hydroxocobalamin",
"      </a>",
"      is available it is the preferred therapy, and we recommend the following treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"       Sodium thiosulfate",
"      </a>",
"      (25 percent) 1.65",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      IV, and",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"       Hydroxocobalamin",
"      </a>",
"      70",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV (5 g is the standard adult dose)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients without contraindication to nitrites, in countries where",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"       hydroxocobalamin",
"      </a>",
"      is not available, and the Akorn Cyanide Antidote Package is available, we recommend the following treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/1/33813?source=see_link\">",
"       Amyl nitrite",
"      </a>",
"      inhaled by the patient (held under the patient's nose or via the endotracheal tube) for 30 seconds of each minute, for three minutes",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=see_link\">",
"       Sodium nitrite",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV, and",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"       Sodium thiosulfate",
"      </a>",
"      (25 percent) 1.65",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      IV",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with contraindications to nitrites or with smoke inhalation (pending test results for carboxyhemoglobin), in countries where",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"       hydroxocobalamin",
"      </a>",
"      is not available, we recommend the following treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"       Sodium thiosulfate",
"      </a>",
"      (25 percent) 1.65",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      IV only",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In countries where 4-dimethylaminophenol (4-DMAP) or dicobalt edetate is available, and there are no contraindications to either drug, and neither",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"       hydroxocobalamin",
"      </a>",
"      nor the Taylor Cyanide Antidote Package is available, we recommend the following treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      4-DMAP (5 percent) 5 mL IV over one minute",
"     </li>",
"     <li>",
"      OR, if 4-DMAP is unavailable,",
"     </li>",
"     <li>",
"      Dicobalt edetate (1.5 percent) 20 mL IV over one minute,",
"      <strong>",
"       ONLY",
"      </strong>",
"      if cyanide poisoning is highly suspected or confirmed",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Association of Poison Control Centers. Toxic Exposure Surveillance System. Annual Reports 1993-2002. www.aapcc.org",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/2\">",
"      M&eacute;garbane B, Delahaye A, Goldgran-Tol&eacute;dano D, Baud FJ. Antidotal treatment of cyanide poisoning. J Chin Med Assoc 2003; 66:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/3\">",
"      Vogel SN, Sultan TR, Ten Eyck RP. Cyanide poisoning. Clin Toxicol 1981; 18:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/4\">",
"      Bismuth C, Baud FJ, Djeghout H, et al. Cyanide poisoning from propionitrile exposure. J Emerg Med 1987; 5:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/5\">",
"      Weger NP. Treatment of cyanide poisoning with 4-dimethylaminophenol (DMAP)--experimental and clinical overview. Fundam Appl Toxicol 1983; 3:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/6\">",
"      Walsh DW, Eckstein M. Hydrogen cyanide in fire smoke: an underappreciated threat. Emerg Med Serv 2004; 33:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/7\">",
"      Sauer SW, Keim ME. Hydroxocobalamin: improved public health readiness for cyanide disasters. Ann Emerg Med 2001; 37:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/8\">",
"      Cummings TF. The treatment of cyanide poisoning. Occup Med (Lond) 2004; 54:82.",
"     </a>",
"    </li>",
"    <li>",
"     Sullivan, JB, Krieger, CR. Clinical Environmental Health and Toxic Exposures, 2nd, Lippincott Williams and Wilkins, Philadelphia 2001. p.705.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/10\">",
"      Hall AH, Linden CH, Kulig KW, Rumack BH. Cyanide poisoning from laetrile ingestion: role of nitrite therapy. Pediatrics 1986; 78:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/11\">",
"      O'Brien B, Quigg C, Leong T. Severe cyanide toxicity from 'vitamin supplements'. Eur J Emerg Med 2005; 12:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/12\">",
"      Bromley J, Hughes BG, Leong DC, Buckley NA. Life-threatening interaction between complementary medicines: cyanide toxicity following ingestion of amygdalin and vitamin C. Ann Pharmacother 2005; 39:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/13\">",
"      Litovitz TL, Larkin RF, Myers RA. Cyanide poisoning treated with hyperbaric oxygen. Am J Emerg Med 1983; 1:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/14\">",
"      Gonzales J, Sabatini S. Cyanide poisoning: pathophysiology and current approaches to therapy. Int J Artif Organs 1989; 12:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/15\">",
"      Vesey CJ, Cole PV, Simpson PJ. Cyanide and thiocyanate concentrations following sodium nitroprusside infusion in man. Br J Anaesth 1976; 48:651.",
"     </a>",
"    </li>",
"    <li>",
"     Bryson, PD. Comprehensive Review in Toxicology for Emergency Clinicians, 3rd, Taylor and Francis, Denver 1996. p.352.",
"    </li>",
"    <li>",
"     The New York Poision Control, Center. An Intensive Review Course in Clinical Toxicology, 2005. p.141.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/18\">",
"      Hall AH, Rumack BH. Clinical toxicology of cyanide. Ann Emerg Med 1986; 15:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/19\">",
"      Mizock BA. Lactic acidosis. Dis Mon 1989; 35:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/20\">",
"      TURSKY T, SAJTER V. The influence of potassium cyanide poisoning on the gamma-aminobutyric acid level in rat brain. J Neurochem 1962; 9:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/21\">",
"      Morocco AP. Cyanides. Crit Care Clin 2005; 21:691.",
"     </a>",
"    </li>",
"    <li>",
"     Amdur, MO, Doull, J, Klacessan, CD, et, al. Casarett and Doull's Toxicology: The Basic Science of Poisons, 4th, McGraw-Hill, New York 1991. p.227.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/23\">",
"      Fortin JL, Desmettre T, Manzon C, et al. Cyanide poisoning and cardiac disorders: 161 cases. J Emerg Med 2010; 38:467.",
"     </a>",
"    </li>",
"    <li>",
"     Greenberg, MI, Hamilton, RJ, Phillips, SD. Occupational, Industrial, and Environmental Toxicology, Mosby, St. Louis 1997. p.165.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/25\">",
"      Baud FJ, Borron SW, M&eacute;garbane B, et al. Value of lactic acidosis in the assessment of the severity of acute cyanide poisoning. Crit Care Med 2002; 30:2044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/26\">",
"      Baud FJ, Barriot P, Toffis V, et al. Elevated blood cyanide concentrations in victims of smoke inhalation. N Engl J Med 1991; 325:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/27\">",
"      Johnson RP, Mellors JW. Arteriolization of venous blood gases: a clue to the diagnosis of cyanide poisoning. J Emerg Med 1988; 6:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/28\">",
"      Rella J, Marcus S, Wagner BJ. Rapid cyanide detection using the Cyantesmo kit. J Toxicol Clin Toxicol 2004; 42:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/29\">",
"      Houston M, Hendrickson RG. Decontamination. Crit Care Clin 2005; 21:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/30\">",
"      Lambert RJ, Kindler BL, Schaeffer DJ. The efficacy of superactivated charcoal in treating rats exposed to a lethal oral dose of potassium cyanide. Ann Emerg Med 1988; 17:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/31\">",
"      Mokhlesi B, Corbridge T. Toxicology in the critically ill patient. Clin Chest Med 2003; 24:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/32\">",
"      Thompson JP, Marrs TC. Hydroxocobalamin in cyanide poisoning. Clin Toxicol (Phila) 2012; 50:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/33\">",
"      Borron SW, Baud FJ, Barriot P, et al. Prospective study of hydroxocobalamin for acute cyanide poisoning in smoke inhalation. Ann Emerg Med 2007; 49:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/34\">",
"      Fortin JL, Giocanti JP, Ruttimann M, Kowalski JJ. Prehospital administration of hydroxocobalamin for smoke inhalation-associated cyanide poisoning: 8 years of experience in the Paris Fire Brigade. Clin Toxicol (Phila) 2006; 44 Suppl 1:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/35\">",
"      Hall AH, Rumack BH. Hydroxycobalamin/sodium thiosulfate as a cyanide antidote. J Emerg Med 1987; 5:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/36\">",
"      Forsyth JC, Mueller PD, Becker CE, et al. Hydroxocobalamin as a cyanide antidote: safety, efficacy and pharmacokinetics in heavily smoking normal volunteers. J Toxicol Clin Toxicol 1993; 31:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/37\">",
"      Borron SW, Baud FJ, M&eacute;garbane B, Bismuth C. Hydroxocobalamin for severe acute cyanide poisoning by ingestion or inhalation. Am J Emerg Med 2007; 25:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/38\">",
"      Heitzman J, Shen Q, Cazares J, Illoh O. Transfusion medicine illustrated: hydroxocobalamin-colored plasma. Transfusion 2009; 49:2555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/39\">",
"      Curry SC, Connor DA, Raschke RA. Effect of the cyanide antidote hydroxocobalamin on commonly ordered serum chemistry studies. Ann Emerg Med 1994; 24:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/40\">",
"      DesLauriers CA, Burda AM, Wahl M. Hydroxocobalamin as a cyanide antidote. Am J Ther 2006; 13:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/41\">",
"      Lee J, Mukai D, Kreuter K, et al. Potential interference by hydroxocobalamin on cooximetry hemoglobin measurements during cyanide and smoke inhalation treatments. Ann Emerg Med 2007; 49:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/42\">",
"      Livshits Z, Lugassy DM, Shawn LK, Hoffman RS. Falsely low carboxyhemoglobin level after hydroxocobalamin therapy. N Engl J Med 2012; 367:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/43\">",
"      Uhl W, Nolting A, Golor G, et al. Safety of hydroxocobalamin in healthy volunteers in a randomized, placebo-controlled study. Clin Toxicol (Phila) 2006; 44 Suppl 1:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/44\">",
"      Shepherd G, Velez LI. Role of hydroxocobalamin in acute cyanide poisoning. Ann Pharmacother 2008; 42:661.",
"     </a>",
"    </li>",
"    <li>",
"     Goldfrank, LR, Flomenbaum, NE, Lewin, NA, et, al. Goldfrank's Toxicologic Emergencies, 7th, McGraw-Hill, New York 2002. p.1511.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/46\">",
"      Mokhlesi B, Leikin JB, Murray P, Corbridge TC. Adult toxicology in critical care: Part II: specific poisonings. Chest 2003; 123:897.",
"     </a>",
"    </li>",
"    <li>",
"     Rosen, P, Barkin, RM. Emergency Medicine:  Concepts and Clinical Practice, 3rd, Mosby, St. Louis 1992. p.2682.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/48\">",
"      Lawson-Smith P, Jansen EC, Hilsted L, et al. Effect of acute and delayed hyperbaric oxygen therapy on cyanide whole blood levels during acute cyanide intoxication. Undersea Hyperb Med 2011; 38:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/49\">",
"      Lawson-Smith P, Olsen NV, Hyldegaard O. Hyperbaric oxygen therapy or hydroxycobalamin attenuates surges in brain interstitial lactate and glucose; and hyperbaric oxygen improves respiratory status in cyanide-intoxicated rats. Undersea Hyperb Med 2011; 38:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/50\">",
"      Erdman AR. Is hydroxocobalamin safe and effective for smoke inhalation? Searching for guidance in the haze. Ann Emerg Med 2007; 49:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/18/7466/abstract/51\">",
"      Geller RJ, Barthold C, Saiers JA, Hall AH. Pediatric cyanide poisoning: causes, manifestations, management, and unmet needs. Pediatrics 2006; 118:2146.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 299 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D4C8FA2A70-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_18_7466=[""].join("\n");
var outline_f7_18_7466=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      KINETICS AND METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Delayed sequelae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Chronic cyanide exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87269935\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87269998\">",
"      General testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87270005\">",
"      Specific testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H87270012\">",
"      - Anion gap acidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H87270019\">",
"      - Lactate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H87270026\">",
"      - Venous PO2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H87270033\">",
"      - Cyanide level",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87269650\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Resuscitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Antidotes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Direct cyanide binding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12183682\">",
"      Hydroxocobalamin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12183689\">",
"      Dicobalt edetate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Induction of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Sulfur donors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6019904\">",
"      - Hyperbaric oxygen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Antidotal treatment guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Probable cyanide intoxication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Questionable cyanide intoxication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Empiric treatment for smoke inhalation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      PEDIATRIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H106424559\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Clinical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/299\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/299|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/5/25681\" title=\"figure 1\">",
"      Mitochondrial metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/26/2479\" title=\"figure 2\">",
"      Hemoglobin oxygen dissociation curve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/299|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/15/25853\" title=\"table 1\">",
"      Cyanide poisoning - Rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/39/15996\" title=\"table 2\">",
"      Cyanide sources",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/17/4379\" title=\"table 3\">",
"      Toxic cyanide doses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/28/39372\" title=\"table 4\">",
"      Agents causing methemoglobinemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=related_link\">",
"      Carbon monoxide poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/20/8521?source=related_link\">",
"      Chemical terrorism: Diagnosis and treatment of exposure to chemical weapons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=related_link\">",
"      Clinical features, diagnosis, and treatment of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=related_link\">",
"      Gastrointestinal decontamination of poisoned adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19142?source=related_link\">",
"      Isoniazid: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33176?source=related_link\">",
"      Organophosphate and carbamate poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19913?source=related_link\">",
"      Salicylate (aspirin) poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22790?source=related_link\">",
"      Smoke inhalation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/5/40022?source=related_link\">",
"      Strychnine poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36231?source=related_link\">",
"      Tricyclic antidepressant poisoning",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_18_7467="Grading of esophageal burn";
var content_f7_18_7467=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Grading of esophageal burns from caustic injury",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Injury",
"       </td>",
"       <td class=\"subtitle1\">",
"        Findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grade 0",
"       </td>",
"       <td>",
"        Normal mucosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grade 1 (superficial)",
"       </td>",
"       <td>",
"        Superficial hyperemia and edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grade 2A (transmucosal)",
"       </td>",
"       <td>",
"        Hemorrhage, exudates, linear erosions, blisters, shallow ulcers involving the mucosa and submucosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grade 2B",
"       </td>",
"       <td>",
"        Circumferential burn present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grade 3",
"       </td>",
"       <td>",
"        Deep ulceration, eschar formation with necrosis, full-thickness injury with and without perforation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_18_7467=[""].join("\n");
var outline_f7_18_7467=null;
var title_f7_18_7468="AHA lesion classification";
var content_f7_18_7468=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for American Heart Association lesion classification system and correspondence with classification of gross arterial specimens",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        AHA grade",
"       </td>",
"       <td class=\"subtitle1\">",
"        Criteria",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments and corresponding gross",
"classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Normal artery with or without adaptive intimal thickening; no",
"hold",
"       </td>",
"       <td>",
"        Normal tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Isolated MFCs containing lipid; no extracellular lipid;",
"variable adaptive intimal thickening grossly with lipid staining",
"       </td>",
"       <td>",
"        Initial atherosclerotic lesion, sometimes visible grossly",
"with lipid staining",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        Numerous MFCs, often in layers, with fine particles of",
"extracellular licid; no distinct pools of extracellular lipid: variable",
"adaptive intimal thickening",
"       </td>",
"       <td>",
"        Fatty streak, visible grossly with III staining",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Numerous MFCs with &ge;",
"pools of extracellular lipid; no well-defined core of extracellular",
"lipid",
"       </td>",
"       <td>",
"        Fatty plaque, raised fatty streak, intermediate lesion, or",
"transitional lesion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        Numerous MFGs plus well-defined core of extracellular lipid,",
"but with luminal surface covered by relatively normal intima",
"       </td>",
"       <td>",
"        Atheroma, fibrous plaque, or raised lesion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        Numerous MFCs, well-defined core or multiple cores of",
"extracellular lipid, plus reactive fibrotic cap, vascularization, or",
"calcium",
"       </td>",
"       <td>",
"        Fibroartherema, fibrous plaque, or raised lesion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        All of the above plus surface defect, hematoma, hemorrhage,",
"or thrombosis",
"       </td>",
"       <td>",
"        Complicated lesion",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MFC: macrophage foam cell; AHA: American Heart Association.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_18_7468=[""].join("\n");
var outline_f7_18_7468=null;
var title_f7_18_7469="Prevalence of polyps with age";
var content_f7_18_7469=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prevalence of adenomatous colonic polyps increases with age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 415px; height: 256px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Adenomatous colonic polyps are found in about 25 percent of people by the age of 50; the prevalence continues to increase with increasing age.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Williams AR, Balasooriya BA, Day DW, Gut 1982; 123:835.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_18_7469=[""].join("\n");
var outline_f7_18_7469=null;
var title_f7_18_7470="Contents: Pediatric resuscitation";
var content_f7_18_7470=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric resuscitation",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric resuscitation",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/17/28948\">",
"           Assessment of perfusion in pediatric resuscitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/22/29030\">",
"           Basic airway management in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/43/7864\">",
"           Basic life support in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/18/44328\">",
"           Carbon dioxide monitoring (capnography)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/24/27014\">",
"           Continuous oxygen delivery systems for infants, children, and adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/48/29450\">",
"           Emergent endotracheal intubation in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/16/20746\">",
"           Guidelines for pediatric advanced life support",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/59/41912\">",
"           Hypovolemic shock in children: Initial evaluation and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/51/22327\">",
"           Initial assessment and stabilization of children with respiratory or circulatory compromise",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/49/14104\">",
"           Initial evaluation of shock in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/8/26762\">",
"           Initial management of shock in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/46/26346\">",
"           Neonatal resuscitation in the delivery room",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/57/42901\">",
"           Physiology and classification of shock in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/23/15738\">",
"           Primary drugs in pediatric resuscitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/29/24026\">",
"           Rapid sequence intubation (RSI) in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/2/13354\">",
"           Septic shock: Ongoing management after resuscitation in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/33/4634\">",
"           Septic shock: Rapid recognition and initial resuscitation in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/6/10346\">",
"           Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/7/15481\">",
"           The difficult pediatric airway",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/55/8057\">",
"           Vascular (venous) access for pediatric resuscitation and other pediatric emergencies",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-FA6420AA62-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f7_18_7470=[""].join("\n");
var outline_f7_18_7470=null;
var title_f7_18_7471="Plain xray solitary bone met";
var content_f7_18_7471=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F71563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F71563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Solitary bone metastasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 287px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Metastatic lesions are usually but not always multiple. In this case, a solitary metastasis from a renal cell carcinoma presented following a pathological fracture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel Rosenthal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_18_7471=[""].join("\n");
var outline_f7_18_7471=null;
